BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 2010;341:c3369. [PMID: 20634346 DOI: 10.1136/bmj.c3369] [Cited by in Crossref: 436] [Cited by in F6Publishing: 472] [Article Influence: 36.3] [Reference Citation Analysis]
Number Citing Articles
1 Zheng J, Sun Q, Zhang J, Ng SC. The role of gut microbiome in inflammatory bowel disease diagnosis and prognosis. UEG Journal 2022. [DOI: 10.1002/ueg2.12338] [Reference Citation Analysis]
2 Gunawan S, Elger T, Loibl J, Fererberger T, Sommersberger S, Kandulski A, Müller M, Tews HC, Buechler C. Urinary chemerin as a potential biomarker for inflammatory bowel disease. Front Med 2022;9. [DOI: 10.3389/fmed.2022.1058108] [Reference Citation Analysis]
3 Xu W, Zhang Y, Zhao W, Chen J, Maas K, Hussain N, Henderson WA, Cong X. Trends of fecal calprotectin levels and associations with early life experience in preterm infants. Interdisciplinary Nursing Research 2022;1:36-42. [DOI: 10.1097/nr9.0000000000000006] [Reference Citation Analysis]
4 Li M, Zhang R, Xin M, Xu Y, Liu S, Yu B, Zhang B, Liu J. Discovery and Validation of Potential Serum Biomarkers with Pro-Inflammatory and DNA Damage Activities in Ulcerative Colitis: A Comprehensive Untargeted Metabolomic Study. Metabolites 2022;12:997. [DOI: 10.3390/metabo12100997] [Reference Citation Analysis]
5 Akutko K, Iwańczak B. Evaluation of Fecal Calprotectin, Serum C-Reactive Protein, Erythrocyte Sedimentation Rate, Seromucoid and Procalcitonin in the Diagnostics and Monitoring of Crohn's Disease in Children. J Clin Med 2022;11:6086. [PMID: 36294408 DOI: 10.3390/jcm11206086] [Reference Citation Analysis]
6 Domislovic V, Høg Mortensen J, Lindholm M, Kaarsdal MA, Brinar M, Barisic A, Manon-jensen T, Krznaric Z. Inflammatory Biomarkers of Extracellular Matrix Remodeling and Disease Activity in Crohn’s Disease and Ulcerative Colitis. JCM 2022;11:5907. [DOI: 10.3390/jcm11195907] [Reference Citation Analysis]
7 Castiglione V, Berodes M, Lukas P, Louis E, Cavalier E, Lutteri L. New Faecal Calprotectin Assay by IDS: Validation and Comparison to DiaSorin Method. Diagnostics 2022;12:2338. [DOI: 10.3390/diagnostics12102338] [Reference Citation Analysis]
8 Heston MB, Hanslik KL, Zarbock KR, Harding SJ, Davenport-sis NJ, Kerby RL, Chin N, Sun Y, Hoeft A, Deming Y, Vogt NM, Betthauser TJ, Johnson SC, Asthana S, Kollmorgen G, Suridjan I, Wild N, Zetterberg H, Blennow K, Rey FE, Bendlin BB, Ulland TK. Gut inflammation associated with age and Alzheimer’s disease pathology.. [DOI: 10.1101/2022.09.21.22280179] [Reference Citation Analysis]
9 Hauzer W, Gnus J, Rosińczuk J. Relationship between the Levels of Calprotectin and Soluble Receptor for Advanced Glycation End Products with Abdominal Aortic Aneurysm Diameter: A Preliminary Clinical Trial. J Clin Med 2022;11:5448. [PMID: 36143093 DOI: 10.3390/jcm11185448] [Reference Citation Analysis]
10 Al-ani AH, Vaughan R, Christensen B, Bryant RV, Novak KL. Treat to transmural healing: how to incorporate intestinal ultrasound into the treatment of inflammatory bowel disease. BJR 2022;95. [DOI: 10.1259/bjr.20211174] [Reference Citation Analysis]
11 Vorel ES, Mehta JJ, Russo ME, Muego MP, Borek RC, Kelly JA, Greenfield ME. A 7-Year-Old With Persistent Fever and Cough. Pediatrics 2022;150. [DOI: 10.1542/peds.2021-050751] [Reference Citation Analysis]
12 Bonner C, Pickering GAE. Rectal bleeding. InnovAiT 2022. [DOI: 10.1177/17557380221118946] [Reference Citation Analysis]
13 Kim JH, Yi DY, Lee YM, Choi YJ, Kim JY, Hong YH, Park JY, Kim SY, Lee NM, Yun SW, Chae SA, Lim IS, Choi ES, Jeong IS. Association between body mass index and fecal calprotectin levels in children and adolescents with irritable bowel syndrome. Medicine (Baltimore) 2022;101:e29968. [PMID: 35960084 DOI: 10.1097/MD.0000000000029968] [Reference Citation Analysis]
14 Makaro A, Dziki Ł, Fichna J, Włodarczyk M. On the Way to Improve Diagnostic Marker Panel for Acute Appendicitis in Adults: the Role of Calprotectin. Indian J Surg 2022;84:634-639. [DOI: 10.1007/s12262-021-03063-y] [Reference Citation Analysis]
15 Fiorino G, Danese S, Peyrin-Biroulet L, Sans M, Bonelli F, Calleri M, Zierold C, Pollastro R, Moretti F, Malesci A. LIAISON® Calprotectin for the prediction of relapse in quiescent ulcerative colitis: The EuReCa study. United European Gastroenterol J 2022. [PMID: 35789124 DOI: 10.1002/ueg2.12268] [Reference Citation Analysis]
16 Bolotova EV, Yumukyan KA, Dudnikova AV, Gilevich IV. Diagnostic power of laboratory methods for assessing ulcerative colitis severity: A prospective comparative study. Kuban nauсh med vestnik 2022;29:14-29. [DOI: 10.25207/1608-6228-2022-29-3-14-29] [Reference Citation Analysis]
17 Bolotova EV, Yumukyan KA, Dudnikova AV. Comparison of the diagnostic capabilities of fecal and serum markers in determining the severity of an ulcerative colitis attack. Kazan Med J 2022;103:409-417. [DOI: 10.17816/kmj2022-409] [Reference Citation Analysis]
18 Güven B, İssi F, Sağ E, Buruk K, Çakır M. Impact of Fecal Calprotectin Measurement for Inflammatory Bowel Disease in Children with Alarm Symptoms. jpr 2022;9:126-131. [DOI: 10.4274/jpr.galenos.2021.99907] [Reference Citation Analysis]
19 Fabi M, Filice E, Andreozzi L, Mattesini BE, Rizzello A, Palleri D, Dajti E, Zagari RM, Lanari M. Combination of fecal calprotectin and initial coronary dimensions to predict coronary artery lesions persistence in Kawasaki disease. Sci Rep 2022;12. [DOI: 10.1038/s41598-022-12702-7] [Reference Citation Analysis]
20 Rydell N, Ekoff H, Hellström PM, Movérare R. Measurement of Serum IgG Anti-Integrin αvβ6 Autoantibodies Is a Promising Tool in the Diagnosis of Ulcerative Colitis. J Clin Med 2022;11:1881. [PMID: 35407486 DOI: 10.3390/jcm11071881] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Sturm A, Atreya R, Bettenworth D, Bokemeyer B, Dignaß A, Ehehalt R, Germer C, Grunert PC, Helwig U, Herrlinger K, Kienle P, Kreis ME, Kucharzik T, Langhorst J, Maaser C, Ockenga J, Ott C, Siegmund B, Zeißig S, Stallmach A; Collaborators:. Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – August 2021 – AWMF-Registernummer: 021-004. Z Gastroenterol 2022;60:332-418. [PMID: 35263784 DOI: 10.1055/a-1713-3941] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
22 Feng J, Li J, Li Y, Jin Y, Du F, Chen X. Elevated Serum D-Dimer May Reflect the Presence of Gut Inflammation in Spondyloarthritis. Front Med 2022;8:816422. [DOI: 10.3389/fmed.2021.816422] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 D. R. K, K. M. G. A REVIEW ON ROLE OF MARKERS IN DIABETES MELLITUS AND ASSOCIATED MICRO AND MACROVASCULAR COMPLICATIONS. Int J Curr Pharm Sci 2022. [DOI: 10.22159/ijcpr.2022v14i1.44108] [Reference Citation Analysis]
24 Jaffray B. Crohn’s Disease. Handbook of Pediatric Surgery 2022. [DOI: 10.1007/978-3-030-84467-7_55] [Reference Citation Analysis]
25 Rundle AL, Baron N, John RM. Care of the Child with a Gastrointestinal Disorder. Pediatric Diagnostic Labs for Primary Care: An Evidence-based Approach 2022. [DOI: 10.1007/978-3-030-90642-9_9] [Reference Citation Analysis]
26 Aloi M, Cucchiara S. Crohn’s Disease. Textbook of Pediatric Gastroenterology, Hepatology and Nutrition 2022. [DOI: 10.1007/978-3-030-80068-0_28] [Reference Citation Analysis]
27 Trasolini R, Zhu K, Klemm N, Park S, Salh B. Fecal Leukocyte Esterase, an Alternative Biomarker to Fecal Calprotectin in Inflammatory Bowel Disease: A Pilot Series. Gastro Hep Advances 2022;1:45-51. [DOI: 10.1016/j.gastha.2021.10.006] [Reference Citation Analysis]
28 Shultz S, Britnell JA, Harvey N. Untapped potential of physiology, behaviour and immune markers to predict range dynamics and marginality. Ecol Evol 2021;11:16446-61. [PMID: 34938448 DOI: 10.1002/ece3.8331] [Reference Citation Analysis]
29 Wagatsuma K, Yokoyama Y, Nakase H. Role of Biomarkers in the Diagnosis and Treatment of Inflammatory Bowel Disease. Life (Basel) 2021;11:1375. [PMID: 34947906 DOI: 10.3390/life11121375] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Wetwittayakhlang P, Lontai L, Gonczi L, Golovics PA, Hahn GD, Bessissow T, Lakatos PL. Treatment Targets in Ulcerative Colitis: Is It Time for All In, including Histology? J Clin Med 2021;10:5551. [PMID: 34884252 DOI: 10.3390/jcm10235551] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
31 Ibrahim HS, Salem AI, Ahmed NMAE, El-Taweel HA. Pre-and post-treatment evaluation of intestinal inflammation in Giardia and Blastocystis infected children: a community-based study. J Parasit Dis 2021;45:1026-33. [PMID: 34789986 DOI: 10.1007/s12639-021-01398-7] [Reference Citation Analysis]
32 Nevejan L, Mylemans M, Vander Cruyssen B, Stubbe M, Van Den Bremt S, Hofman L, Infantino M, Manfredi M, Bossuyt X, Van Hoovels L. Pre-analytical recommendations and reference values for circulating calprotectin are sample type and assay dependent. Clin Chem Lab Med 2021. [PMID: 34714981 DOI: 10.1515/cclm-2021-0998] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
33 Mellett L, Khader SA. S100A8/A9 in COVID-19 pathogenesis: Impact on clinical outcomes. Cytokine Growth Factor Rev 2021:S1359-6101(21)00076-9. [PMID: 34728150 DOI: 10.1016/j.cytogfr.2021.10.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 12.0] [Reference Citation Analysis]
34 Jukic A, Bakiri L, Wagner EF, Tilg H, Adolph TE. Calprotectin: from biomarker to biological function. Gut 2021;70:1978-88. [PMID: 34145045 DOI: 10.1136/gutjnl-2021-324855] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 46.0] [Reference Citation Analysis]
35 Pero-Gascon R, Hemeryck LY, Poma G, Falony G, Nawrot TS, Raes J, Vanhaecke L, De Boevre M, Covaci A, De Saeger S. FLEXiGUT: Rationale for exposomics associations with chronic low-grade gut inflammation. Environ Int 2021;158:106906. [PMID: 34607040 DOI: 10.1016/j.envint.2021.106906] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
36 Yang RX, Song WJ, Wu ZQ, Goyal H, Xu HG. Association of Serum Neuron-Specific Enolase and C-Reactive Protein With Disease Location and Endoscopic Inflammation Degree in Patients With Crohn's Disease. Front Med (Lausanne) 2021;8:663920. [PMID: 34513858 DOI: 10.3389/fmed.2021.663920] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
37 Barbosa JA, Rodrigues LA, Columbus DA, Aguirre JCP, Harding JCS, Cantarelli VS, Costa MO. Experimental infectious challenge in pigs leads to elevated fecal calprotectin levels following colitis, but not enteritis. Porcine Health Manag 2021;7:48. [PMID: 34429170 DOI: 10.1186/s40813-021-00228-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
38 Wang L, Guo H, Li J, He S, Yang G, Li E. Adenovirus is prevalent in juvenile polyps and correlates with low vitamin D receptor expression. Pediatr Res 2021. [PMID: 34400787 DOI: 10.1038/s41390-021-01697-y] [Reference Citation Analysis]
39 Gacesa R, Vich Vila A, Collij V, Mujagic Z, Kurilshikov A, Voskuil MD, Festen EAM, Wijmenga C, Jonkers DMAE, Dijkstra G, Fu J, Zhernakova A, Imhann F, Weersma RK. A combination of fecal calprotectin and human beta-defensin 2 facilitates diagnosis and monitoring of inflammatory bowel disease. Gut Microbes 2021;13:1943288. [PMID: 34313538 DOI: 10.1080/19490976.2021.1943288] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
40 Simsek C, Erul E, Balaban HY. Role of gastrointestinal system on transmission and pathogenesis of SARS-CoV-2. World J Clin Cases 2021; 9(20): 5427-5434 [PMID: 34307596 DOI: 10.12998/wjcc.v9.i20.5427] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
41 Kvedaraite E. Neutrophil-T cell crosstalk in inflammatory bowel disease. Immunology 2021. [PMID: 34240423 DOI: 10.1111/imm.13391] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
42 Nakase H, Uchino M, Shinzaki S, Matsuura M, Matsuoka K, Kobayashi T, Saruta M, Hirai F, Hata K, Hiraoka S, Esaki M, Sugimoto K, Fuji T, Watanabe K, Nakamura S, Inoue N, Itoh T, Naganuma M, Hisamatsu T, Watanabe M, Miwa H, Enomoto N, Shimosegawa T, Koike K. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol 2021;56:489-526. [PMID: 33885977 DOI: 10.1007/s00535-021-01784-1] [Cited by in Crossref: 58] [Cited by in F6Publishing: 44] [Article Influence: 58.0] [Reference Citation Analysis]
43 Nusbaum KB, Korman AM, Tyler K, Kaffenberger J, Trinidad J, Kaffenberger BH. In vitro diagnostics for the medical dermatologist. Part I: Autoimmune tests. J Am Acad Dermatol 2021;85:287-98. [PMID: 33852926 DOI: 10.1016/j.jaad.2021.02.090] [Reference Citation Analysis]
44 Ho SSC, Ross M, Keenan JI, Day AS. Fecal Calprotectin in Combination With Standard Blood Tests in the Diagnosis of Inflammatory Bowel Disease in Children. Front Pediatr 2020;8:609279. [PMID: 33748035 DOI: 10.3389/fped.2020.609279] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
45 Campbell R. Nurse-led development of a rapid-access clinic and referral pathway for suspected inflammatory bowel disease. Gastrointestinal Nursing 2021;19:28-34. [DOI: 10.12968/gasn.2021.19.2.28] [Reference Citation Analysis]
46 Natarajan EV, Aronson PL, Berkwitt AK. The Cost of Diagnostic Delay and Error. Hosp Pediatr 2021;11:e38-41. [PMID: 33632747 DOI: 10.1542/hpeds.2020-003046] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Malvão LDR, Madi K, Esberard BC, de Amorim RF, Silva KDS, Farias E Silva K, de Souza HSP, Carvalho ATP. Fecal calprotectin as a noninvasive test to predict deep remission in patients with ulcerative colitis. Medicine (Baltimore) 2021;100:e24058. [PMID: 33546007 DOI: 10.1097/MD.0000000000024058] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
48 Wyness SP, Lin L, Jensen R, Bird J, Norgyal T, Jensen G, Johnson LM. Clinical and Analytical Verification of an Automated Fecal Calprotectin Immunoassay with Extraction Device. J Appl Lab Med 2021;6:931-41. [PMID: 33582792 DOI: 10.1093/jalm/jfaa236] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
49 Orfei M, Gasparetto M, Hensel KO, Zellweger F, Heuschkel RB, Zilbauer M. Guidance on the interpretation of faecal calprotectin levels in children. PLoS One 2021;16:e0246091. [PMID: 33571226 DOI: 10.1371/journal.pone.0246091] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
50 Aziz I, Simrén M. The overlap between irritable bowel syndrome and organic gastrointestinal diseases. The Lancet Gastroenterology & Hepatology 2021;6:139-48. [DOI: 10.1016/s2468-1253(20)30212-0] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 23.0] [Reference Citation Analysis]
51 Sandhu K, Naik S, Ayling RM. Use of faecal immunochemical testing as an alternative to faecal calprotectin in children. Ann Clin Biochem 2021;58:230-5. [PMID: 33412889 DOI: 10.1177/0004563221989359] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Wong NACS, Wallage MJ, Virgo P, Lowes H. Sampling endoscopically normal large bowel mucosa from patients presenting with elevated faecal calprotectin levels is not clinically justified. J Clin Pathol 2021:jclinpath-2020-207343. [PMID: 33509947 DOI: 10.1136/jclinpath-2020-207343] [Reference Citation Analysis]
53 D'Amico F, Nancey S, Danese S, Peyrin-Biroulet L. A Practical Guide for Faecal Calprotectin Measurement: Myths and Realities. J Crohns Colitis 2021;15:152-61. [PMID: 32392336 DOI: 10.1093/ecco-jcc/jjaa093] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
54 Campeotto F, Elie C, Rousseau C, Giuseppi A, Hachem T, Gobalakichenane P, Le Touzey M, de Stefano M, Butel MJ, Kapel N. Faecal calprotectin and gut microbiota do not predict enteropathy in very preterm infants. Acta Paediatr 2021;110:109-16. [PMID: 32418251 DOI: 10.1111/apa.15354] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
55 Hano T, Ito M, Ito K, Uchida M. Alterations of stool metabolome, phenome, and microbiome of the marine fish, red sea bream, Pagrus major, following exposure to phenanthrene: A non-invasive approach for exposure assessment. Science of The Total Environment 2021;752:141796. [DOI: 10.1016/j.scitotenv.2020.141796] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
56 Lima SMAAL, Yazbek MA. Exames complementares das entesopatias. Parte 1 – Biomarcadores. Rev Paul Reumatol 2020. [DOI: 10.46833/reumatologiasp.2020.19.4.60-64] [Reference Citation Analysis]
57 Szałwińska P, Włodarczyk J, Spinelli A, Fichna J, Włodarczyk M. IBS-Symptoms in IBD Patients-Manifestation of Concomitant or Different Entities. J Clin Med 2020;10:E31. [PMID: 33374388 DOI: 10.3390/jcm10010031] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
58 Shentova-eneva R, Velikova T. Laboratory Assessment of Disease Activity in Pediatric Patients with Inflammatory Bowel Disease: What’s New? Gastroenterology Insights 2020;11:58-71. [DOI: 10.3390/gastroent11020009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
59 Kucharzik T, Dignass AU, Atreya R, Bokemeyer B, Esters P, Herrlinger K, Kannengießer K, Kienle P, Langhorst J, Lügering A, Schreiber S, Stallmach A, Stein J, Sturm A, Teich N, Siegmund B; Collaborators:. Aktualisierte S3-Leitlinie Colitis ulcerosa – Living Guideline. Z Gastroenterol 2020;58:e241-326. [PMID: 33260237 DOI: 10.1055/a-1296-3444] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
60 Juliao-baños F, Grillo A CF, Pineda Ovalle LF, Otero Regino. W, Galiano de Sánchez. MT, García Duperly. R, Vallejo O. MT, Torres Amaya. M. Guía de práctica clínica para el tratamiento de la enfermedad de Crohn en población adulta. Rev Colomb Gastroenterol 2020;35:63-200. [DOI: 10.22516/25007440.637] [Reference Citation Analysis]
61 Oosterwijk MM, Bakker SJL, Nilsen T, Navis G, Laverman GD. Determinants of Increased Serum Calprotectin in Patients with Type 2 Diabetes Mellitus. Int J Mol Sci 2020;21:E8075. [PMID: 33138021 DOI: 10.3390/ijms21218075] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
62 Lloyd-McLennan AM, Ali S, Kittler NW. Prevalence of inflammatory bowel disease among pediatric patients with hidradenitis suppurativa and the potential role of screening with fecal calprotectin. Pediatr Dermatol 2021;38:98-102. [PMID: 33099810 DOI: 10.1111/pde.14417] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
63 Soleymani S, Moradkhani A, Eftekhari M, Rahmanian F, Moosavy SH. Correlation between Clinical Symptoms and Lab Tests with Endoscopic Severity Indexes in Patients with Inflammatory Bowel Diseases. Middle East J Dig Dis 2020;12:162-70. [PMID: 33062221 DOI: 10.34172/mejdd.2020.178] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
64 Park SY. Age-Related Fecal Calprotectin Concentrations in Healthy Adults. Korean J Clin Lab Sci 2020;52:181-187. [DOI: 10.15324/kjcls.2020.52.3.181] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
65 Hussain ZU, Comerford R, Comerford F, Ng N, Ng D, Khan A, Lees C, Hussain A. A Comparison of Machine Learning Approaches for Predicting the Progression of Crohn’s Disease. 2020 IEEE Student Conference on Research and Development (SCOReD) 2020. [DOI: 10.1109/scored50371.2020.9251019] [Reference Citation Analysis]
66 Kobayashi T, Siegmund B, Le Berre C, Wei SC, Ferrante M, Shen B, Bernstein CN, Danese S, Peyrin-Biroulet L, Hibi T. Ulcerative colitis.Nat Rev Dis Primers. 2020;6:74. [PMID: 32913180 DOI: 10.1038/s41572-020-0205-x] [Cited by in Crossref: 260] [Cited by in F6Publishing: 276] [Article Influence: 130.0] [Reference Citation Analysis]
67 Kang EA, Chun J, Im JP, Lee HJ, Han K, Soh H, Park S, Kim JS. Anemia is associated with the risk of Crohn's disease, not ulcerative colitis: A nationwide population-based cohort study. PLoS One 2020;15:e0238244. [PMID: 32898174 DOI: 10.1371/journal.pone.0238244] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
68 Kalla R, Adams A, Bergemalm D, Vatn S, Kennedy N, Ricanek P, Lindstrom J, Ocklind A, Hjelm F, Ventham N, Ho G, Petren C, Repsilber D, Söderholm J, Pierik M, D’amato M, Gomollón F, Olbjorn C, Jahnsen J, Vatn M, Halfvarson J, Satsangi J, IBD-Character Consortium. Serum proteomic profiling at diagnosis predicts clinical course, and need for intensification of treatment in inflammatory bowel disease.. [DOI: 10.1101/2020.08.31.276162] [Reference Citation Analysis]
69 Khaki-Khatibi F, Qujeq D, Kashifard M, Moein S, Maniati M, Vaghari-Tabari M. Calprotectin in inflammatory bowel disease. Clin Chim Acta 2020;510:556-65. [PMID: 32818491 DOI: 10.1016/j.cca.2020.08.025] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 9.0] [Reference Citation Analysis]
70 Zhang X, Ning Z, Mayne J, Yang Y, Deeke SA, Walker K, Farnsworth CL, Stokes MP, Couture JF, Mack D, Stintzi A, Figeys D. Widespread protein lysine acetylation in gut microbiome and its alterations in patients with Crohn's disease. Nat Commun 2020;11:4120. [PMID: 32807798 DOI: 10.1038/s41467-020-17916-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
71 Laserna-Mendieta EJ, Lucendo AJ. Faecal calprotectin in inflammatory bowel diseases: a review focused on meta-analyses and routine usage limitations. Clin Chem Lab Med 2019;57:1295-307. [PMID: 30785706 DOI: 10.1515/cclm-2018-1063] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
72 Wiestler M, Kockelmann F, Kück M, Kerling A, Tegtbur U, Manns MP, Attaran-Bandarabadi M, Bachmann O. Quality of Life Is Associated With Wearable-Based Physical Activity in Patients With Inflammatory Bowel Disease: A Prospective, Observational Study. Clin Transl Gastroenterol 2019;10:e00094. [PMID: 31770137 DOI: 10.14309/ctg.0000000000000094] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
73 Malesza IJ, Malesza M, Krela-Kaźmierczak I, Zielińska A, Souto EB, Dobrowolska A, Eder P. Primary Humoral Immune Deficiencies: Overlooked Mimickers of Chronic Immune-Mediated Gastrointestinal Diseases in Adults. Int J Mol Sci 2020;21:E5223. [PMID: 32718006 DOI: 10.3390/ijms21155223] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
74 Johnson LM, White SK, Schmidt RL. Are calprotectin and lactoferrin equivalent screening tests for inflammatory bowel disease? Clin Chim Acta 2020;510:191-5. [PMID: 32673669 DOI: 10.1016/j.cca.2020.07.021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
75 Vicente-Steijn R, Jansen JM, Bisheshar R, Haagen IA. Analytical and clinical performance of the fully-automated LIAISONXL calprotectin immunoassay from DiaSorin in IBD patients. Pract Lab Med 2020;21:e00175. [PMID: 32637525 DOI: 10.1016/j.plabm.2020.e00175] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
76 Goold E, Pearson L, Johnson LM. Can fecal calprotectin serve as a screen for necrotizing enterocolitis in infants? Clin Biochem 2020;84:51-4. [PMID: 32628920 DOI: 10.1016/j.clinbiochem.2020.06.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
77 Mckechnie T, Lee Y, Kruse C, Ramji K, Springer JE, Wood T, Doumouras AG, Hong D, Eskicioglu C. The role of fecal calprotectin in the diagnosis of acute pouchitis following IPAA for ulcerative colitis: a systematic clinical review. Int J Colorectal Dis 2020;35:1619-28. [DOI: 10.1007/s00384-020-03669-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
78 Bosch S, Wintjens DSJ, Wicaksono A, Kuijvenhoven J, van der Hulst R, Stokkers P, Daulton E, Pierik MJ, Covington JA, de Meij TGJ, de Boer NKH. The faecal scent of inflammatory bowel disease: Detection and monitoring based on volatile organic compound analysis. Dig Liver Dis 2020;52:745-52. [PMID: 32402741 DOI: 10.1016/j.dld.2020.03.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
79 Lorenzin M, Ometto F, Ortolan A, Felicetti M, Favero M, Doria A, Ramonda R. An update on serum biomarkers to assess axial spondyloarthritis and to guide treatment decision. Ther Adv Musculoskelet Dis 2020;12:1759720X20934277. [PMID: 32636944 DOI: 10.1177/1759720X20934277] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
80 Trotter AJ, Dean R, Whitehouse CE, Mikalsen J, Hill C, Brunton-Sim R, Kay GL, Shakokani M, Durst AZE, Wain J, McNamara I, O'Grady J. Preliminary evaluation of a rapid lateral flow calprotectin test for the diagnosis of prosthetic joint infection. Bone Joint Res 2020;9:202-10. [PMID: 32566141 DOI: 10.1302/2046-3758.95.BJR-2019-0213.R1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
81 Walker GJ, Chanchlani N, Thomas A, Lin S, Moore L, Heerasing NM, Hendy P, Abdelrahim M, Mole S, Perry MH, Mcdonald TJ, Bewshea CM, Hart JW, Russell RK, Ahmad T, Goodhand JR, Kennedy NA. Primary care faecal calprotectin testing in children with suspected inflammatory bowel disease: a diagnostic accuracy study. Arch Dis Child 2020;105:957-63. [PMID: 32424002 DOI: 10.1136/archdischild-2019-317823] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
82 Lué A, Hijos G, Sostres C, Perales A, Navarro M, Barra MV, Mascialino B, Andalucia C, Puente JJ, Lanas Á, Gomollon F. The combination of quantitative faecal occult blood test and faecal calprotectin is a cost-effective strategy to avoid colonoscopies in symptomatic patients without relevant pathology. Therap Adv Gastroenterol 2020;13:1756284820920786. [PMID: 32523623 DOI: 10.1177/1756284820920786] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
83 Nakada N, Mikami T, Horie K, Nagashio R, Sakurai Y, Sanoyama I, Yoshida T, Sada M, Kobayashi K, Sato Y, Okayasu I, Murakumo Y. Expression of CA2 and CA9 carbonic anhydrases in ulcerative colitis and ulcerative colitis-associated colorectal cancer. Pathol Int. 2020;70:523-532. [PMID: 32410301 DOI: 10.1111/pin.12949] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
84 Yeshi K, Ruscher R, Hunter L, Daly NL, Loukas A, Wangchuk P. Revisiting Inflammatory Bowel Disease: Pathology, Treatments, Challenges and Emerging Therapeutics Including Drug Leads from Natural Products. J Clin Med 2020;9:E1273. [PMID: 32354192 DOI: 10.3390/jcm9051273] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 23.0] [Reference Citation Analysis]
85 Brennan Laing B, Cavadino A, Ellett S, Ferguson LR. Effects of an Omega-3 and Vitamin D Supplement on Fatty Acids and Vitamin D Serum Levels in Double-Blinded, Randomized, Controlled Trials in Healthy and Crohn's Disease Populations. Nutrients 2020;12:E1139. [PMID: 32325778 DOI: 10.3390/nu12041139] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
86 Nam B, Kim SA, Park SD, Kim HJ, Kim JS, Bae CH, Kim JY, Nam W, Lee JL, Sim JH. Regulatory effects of Lactobacillus plantarum HY7714 on skin health by improving intestinal condition. PLoS One 2020;15:e0231268. [PMID: 32275691 DOI: 10.1371/journal.pone.0231268] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
87 Park SM, Won DD, Lee BJ, Escobedo D, Esteva A, Aalipour A, Ge TJ, Kim JH, Suh S, Choi EH, Lozano AX, Yao C, Bodapati S, Achterberg FB, Kim J, Park H, Choi Y, Kim WJ, Yu JH, Bhatt AM, Lee JK, Spitler R, Wang SX, Gambhir SS. A mountable toilet system for personalized health monitoring via the analysis of excreta. Nat Biomed Eng 2020;4:624-35. [PMID: 32251391 DOI: 10.1038/s41551-020-0534-9] [Cited by in Crossref: 66] [Cited by in F6Publishing: 68] [Article Influence: 33.0] [Reference Citation Analysis]
88 Roda G, Chien Ng S, Kotze PG, Argollo M, Panaccione R, Spinelli A, Kaser A, Peyrin-Biroulet L, Danese S. Crohn's disease.Nat Rev Dis Primers. 2020;6:22. [PMID: 32242028 DOI: 10.1038/s41572-020-0156-2] [Cited by in Crossref: 162] [Cited by in F6Publishing: 172] [Article Influence: 81.0] [Reference Citation Analysis]
89 Apine I, Pirksta I, Pitura R, Pokrotnieks J, Puķīte I, Krūmiņa G. Repeatability of Magnetic Resonance Measurements Used for Estimating Crohn’s Disease Activity. Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences. 2020;74:75-82. [DOI: 10.2478/prolas-2020-0012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
90 Kyle BD, Agbor TA, Sharif S, Chauhan U, Marshall J, Halder SLS, Ip S, Khan WI. Fecal Calprotectin, CRP and Leucocytes in IBD Patients: Comparison of Biomarkers With Biopsy Results. J Can Assoc Gastroenterol 2021;4:84-90. [PMID: 33855266 DOI: 10.1093/jcag/gwaa009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
91 Borg-Bartolo SP, Boyapati RK, Satsangi J, Kalla R. Precision medicine in inflammatory bowel disease: concept, progress and challenges. F1000Res. 2020;9. [PMID: 32047622 DOI: 10.12688/f1000research.20928.1] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 15.5] [Reference Citation Analysis]
92 Zeevenhooven J, Rexwinkel R, Tromp E, Haver B, Groeneweg M, Benninga MA, Vlieger AM. Clinical Evaluation of Inflammatory and Blood Parameters in the Workup of Pediatric Chronic Abdominal Pain. J Pediatr 2020;219:76-82.e3. [PMID: 31987658 DOI: 10.1016/j.jpeds.2019.12.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
93 Lukina GV, Kulakova PI, Novikov AA, Savenkova NA, Alexandrova EA, Volnukhin EV, Kovshik AN. Frequency of inflammatory bowel diseases in patients with ankylosing spondylitis. Medicinskij alfavit 2020;2:12-15. [DOI: 10.33667/2078-5631-2019-2-37(412)-12-15] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
94 Herrlinger K. Labordiagnostik bei CED. Chronisch-entzündliche Darmerkrankungen 2020. [DOI: 10.1007/978-3-662-59104-8_9] [Reference Citation Analysis]
95 Keller K. Medikamentöse Therapie der CED bei Kindern und Jugendlichen. Chronisch-entzündliche Darmerkrankungen 2020. [DOI: 10.1007/978-3-662-59104-8_28] [Reference Citation Analysis]
96 Tokmak S, Harmanci Özakyol A. Elevated Levels of Fecal Calprotectin in Cirrhotic Patients and Spontaneous Bacterial Peritonitis. Düzce Tıp Fakültesi Dergisi 2019. [DOI: 10.18678/dtfd.653549] [Reference Citation Analysis]
97 Hong ST, Koh B, Choi SJ, Yoon E, Pyo MC, Choi JW, Kim MS, Lee EJ, Paik KC, Han MS, Chun HJ, Heo JN, Kim ES, Cho BR. Two-Photon Probe for TNF-α. Assessment of the Transmembrane TNF-α Level in Human Colon Tissue by Two-Photon Microscopy. Anal Chem 2019;91:15769-76. [PMID: 31663332 DOI: 10.1021/acs.analchem.9b04036] [Reference Citation Analysis]
98 Somwaru AS, Khanijow V, Katabathina VS. Magnetic resonance enterography, colonoscopy, and fecal calprotectin correlate in colonic Crohn's disease. BMC Gastroenterol 2019;19:210. [PMID: 31805875 DOI: 10.1186/s12876-019-1125-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
99 Zhou W, Qiao H, Yuan W, Yao Z, Liu K, Wang J, Pang Y. Diagnostic utility of fecal calprotectin in patients presenting to the emergency department with suspected acute appendicitis. Am J Emerg Med 2020;38:2303-7. [PMID: 31780188 DOI: 10.1016/j.ajem.2019.10.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
100 Chmiel C, Senn O, Hasler S, Rosemann T, Rogler G, Zahnd N, Tandjung R, Scherz N, Sulz MC, Vavricka S. Can the CalproQuest predict a positive Calprotectin test? A prospective diagnostic study. PLoS One 2019;14:e0224961. [PMID: 31751360 DOI: 10.1371/journal.pone.0224961] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
101 Ko MS, Rudrapatna VA, Avila P, Mahadevan U. Safety of Flexible Sigmoidoscopy in Pregnant Patients with known or suspected Inflammatory Bowel Disease.. [DOI: 10.1101/19007997] [Reference Citation Analysis]
102 Azramezani Kopi T, Amini Kadijani A, Parsian H, Shahrokh S, Asadzadeh Aghdaei H, Mirzaei A, Balaii H, Zali MR. The value of mRNA expression of S100A8 and S100A9 as blood-based biomarkers of inflammatory bowel disease. Arab J Gastroenterol 2019;20:135-40. [PMID: 31563476 DOI: 10.1016/j.ajg.2019.07.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
103 Motaganahalli S, Beswick L, Con D, van Langenberg DR. Faecal calprotectin delivers on convenience, cost reduction and clinical decision-making in inflammatory bowel disease: a real-world cohort study. Intern Med J 2019;49:94-100. [PMID: 29962008 DOI: 10.1111/imj.14027] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
104 Zhang X, Ning Z, Mayne J, Deeke SA, Walker K, Farnsworth CL, Stokes MP, Mack D, Stintzi A, Figeys D. Deep characterization of the protein lysine acetylation in human gut microbiome and its alterations in patients with Crohn’s disease.. [DOI: 10.1101/772483] [Reference Citation Analysis]
105 Trotter AJ, Dean R, Whitehouse CE, Mikalsen J, Hill C, Brunton-sim R, Kay GL, Shakokhani M, Durst A, Wain J, Mcnamara I, O’grady J. Evaluation of a rapid lateral flow calprotectin test for the diagnosis of prosthetic joint infection.. [DOI: 10.1101/19004473] [Reference Citation Analysis]
106 Xie C, Quan R, Wang L, Chen C, Yan W, Fu Y. Diagnostic value of fecal B cell activating factor in patients with abdominal discomfort. Clin Exp Immunol 2019;198:131-40. [PMID: 31314927 DOI: 10.1111/cei.13350] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
107 Pelkmans LPJ, de Groot MJM, Curvers J. Analytical Performance and Clinicopathologic Correlation of Four Fecal Calprotectin Methods. Am J Clin Pathol 2019;152:392-8. [PMID: 31152542 DOI: 10.1093/ajcp/aqz051] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
108 Kamarudin M. Low-risk bowel cancer symptoms: is it time for FIT? Br J Gen Pract 2019;69:356-357. [DOI: 10.3399/bjgp19x704501] [Reference Citation Analysis]
109 Knyazev OV, Kagramanova AV, Korneeva IA, Noskova KK, Belousov SV, Parfenov AI. The use of fecal calprotectin in monitoring activity of inflammatory bowel diseases. Ter Arkh 2019;91:53-61. [PMID: 31094477 DOI: 10.26442/00403660.2019.04.000229] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
110 Bosch S, Lemmen JP, Menezes R, van der Hulst R, Kuijvenhoven J, Stokkers PC, de Meij TG, de Boer NK. The influence of lifestyle factors on fecal volatile organic compound composition as measured by an electronic nose. J Breath Res 2019;13:046001. [PMID: 31170704 DOI: 10.1088/1752-7163/ab2775] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
111 Velasco Rodríguez-Belvís M, Viada Bris JF, Plata Fernández C, García-Salido A, Asensio Antón J, Domínguez Ortega G, Muñoz Codoceo RA. Normal fecal calprotectin levels in healthy children are higher than in adults and decrease with age. Paediatr Child Health 2020;25:286-92. [PMID: 32765164 DOI: 10.1093/pch/pxz070] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
112 Ricciuto A, Griffiths AM. Clinical value of fecal calprotectin. Crit Rev Clin Lab Sci 2019;56:307-20. [PMID: 31088326 DOI: 10.1080/10408363.2019.1619159] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 12.3] [Reference Citation Analysis]
113 Black CJ, Ford AC. Rational investigations in irritable bowel syndrome. Frontline Gastroenterol 2020;11:140-7. [PMID: 32133113 DOI: 10.1136/flgastro-2019-101211] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
114 Li J, Zhao X, Li X, Lu M, Zhang H. Systematic Review with Meta-Analysis: Fecal Calprotectin as a Surrogate Marker for Predicting Relapse in Adults with Ulcerative Colitis. Mediators Inflamm. 2019;2019:2136501. [PMID: 31275056 DOI: 10.1155/2019/2136501] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
115 Okba AM, Amin MM, Abdelmoaty AS, Ebada HE, Kamel AH, Allam AS, Sobhy OM. Neutrophil/lymphocyte ratio and lymphocyte/monocyte ratio in ulcerative colitis as non-invasive biomarkers of disease activity and severity. Auto Immun Highlights 2019;10:4. [PMID: 32257060 DOI: 10.1186/s13317-019-0114-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
116 Feld L, Glick LR, Cifu AS. Diagnosis and Management of Crohn Disease. JAMA 2019;321:1822-3. [PMID: 30969326 DOI: 10.1001/jama.2019.3684] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
117 Zhang W, Wong CH, Chavannes M, Mohammadi T, Rosenfeld G. Cost-effectiveness of faecal calprotectin used in primary care in the diagnosis of inflammatory bowel disease. BMJ Open 2019;9:e027043. [PMID: 30987989 DOI: 10.1136/bmjopen-2018-027043] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
118 Wegh CAM, de Roos NM, Hovenier R, Meijerink J, Besseling-van der Vaart I, van Hemert S, Witteman BJM. Intestinal Permeability Measured by Urinary Sucrose Excretion Correlates with Serum Zonulin and Faecal Calprotectin Concentrations in UC Patients in Remission. J Nutr Metab. 2019;2019:2472754. [PMID: 31061734 DOI: 10.1155/2019/2472754] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
119 Egea Valenzuela J, Ródenas GA, Sánchez Martínez A. Use of biomarkers in inflammatory bowel disease. Medicina Clínica (English Edition) 2019;152:310-316. [DOI: 10.1016/j.medcle.2018.10.018] [Reference Citation Analysis]
120 Bogere P, Department of Agricultural Convergence Technology, Chonbuk National University, Jeonju, 54896, Korea, Choi YJ, Heo J. Optimization of Fecal Calprotectin Assay for Pig Samples. J Agirc Life Sci 2019;53:93-104. [DOI: 10.14397/jals.2019.53.1.93] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
121 Khanna R, Feagan BG. The Role of Biomarkers in Treatment Algorithms for Ulcerative Colitis (UC). Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune-Mediated Inflammatory Diseases 2019. [DOI: 10.1002/9781119289234.ch2] [Reference Citation Analysis]
122 Simon EG, Wardle R, Thi AA, Eldridge J, Samuel S, Moran GW. Does fecal calprotectin equally and accurately measure disease activity in small bowel and large bowel Crohn's disease? - a systematic review. Intest Res. 2019;. [PMID: 30704158 DOI: 10.5217/ir.2018.00114] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 7.7] [Reference Citation Analysis]
123 Tang Z, Yang Y, Wang X, Meng W, Li X. Meta-analysis of the diagnostic value of Wisteria floribunda agglutinin-sialylated mucin1 and the prognostic role of mucin1 in human cholangiocarcinoma. BMJ Open 2019;9:e021693. [PMID: 30700476 DOI: 10.1136/bmjopen-2018-021693] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
124 Ma C, Battat R, Parker CE, Khanna R, Jairath V, Feagan BG. Update on C-reactive protein and fecal calprotectin: are they accurate measures of disease activity in Crohn’s disease? Expert Review of Gastroenterology & Hepatology 2019;13:319-30. [DOI: 10.1080/17474124.2019.1563481] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 9.0] [Reference Citation Analysis]
125 Franke-vögtlin M, Vavricka S. Differential Diagnosis. Inflammatory Bowel Disease Nursing Manual 2019. [DOI: 10.1007/978-3-319-75022-4_9] [Reference Citation Analysis]
126 Azramezani Kopi T, Shahrokh S, Mirzaei S, Asadzadeh Aghdaei H, Amini Kadijani A. The role of serum calprotectin as a novel biomarker in inflammatory bowel diseases: a review study. Gastroenterol Hepatol Bed Bench 2019;12:183-9. [PMID: 31528300] [Reference Citation Analysis]
127 Barbara G, Grover M, Bercik P, Corsetti M, Ghoshal UC, Ohman L, Rajilić-Stojanović M. Rome Foundation Working Team Report on Post-Infection Irritable Bowel Syndrome. Gastroenterology 2019;156:46-58.e7. [PMID: 30009817 DOI: 10.1053/j.gastro.2018.07.011] [Cited by in Crossref: 109] [Cited by in F6Publishing: 107] [Article Influence: 36.3] [Reference Citation Analysis]
128 Egea Valenzuela J, Antón Ródenas G, Sánchez Martínez A. Use of biomarkers in inflammatory bowel disease. Med Clin (Barc) 2019;152:310-6. [PMID: 30502302 DOI: 10.1016/j.medcli.2018.10.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
129 Caimmi C, Bertoldo E, Venturini A, Caramaschi P, Frulloni L, Ciccocioppo R, Brunelli S, Idolazzi L, Gatti D, Rossini M, Viapiana O. Relationship Between Increased Fecal Calprotectin Levels and Interstitial Lung Disease in Systemic Sclerosis. J Rheumatol 2019;46:274-8. [PMID: 30442820 DOI: 10.3899/jrheum.171445] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
130 Karu N, Deng L, Slae M, Guo AC, Sajed T, Huynh H, Wine E, Wishart DS. A review on human fecal metabolomics: Methods, applications and the human fecal metabolome database. Analytica Chimica Acta 2018;1030:1-24. [DOI: 10.1016/j.aca.2018.05.031] [Cited by in Crossref: 130] [Cited by in F6Publishing: 136] [Article Influence: 32.5] [Reference Citation Analysis]
131 Akobeng AK. Clinical usefulness of the faecal calprotectin test in suspected paediatric inflammatory bowel disease. Acta Paediatr 2018;107:2019-23. [PMID: 29706011 DOI: 10.1111/apa.14374] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
132 Chmiel C, Vavricka SR, Hasler S, Rogler G, Zahnd N, Schiesser S, Tandjung R, Scherz N, Rosemann T, Senn O. Feasibility of an 8-item questionnaire for early diagnosis of inflammatory bowel disease in primary care. J Eval Clin Pract 2019;25:155-62. [PMID: 30324695 DOI: 10.1111/jep.13046] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
133 Bosch S, van Gaal N, Zuurbier RP, Covington JA, Wicaksono AN, Biezeveld MH, Benninga MA, Mulder CJ, de Boer NKH, de Meij TGJ. Differentiation Between Pediatric Irritable Bowel Syndrome and Inflammatory Bowel Disease Based on Fecal Scent: Proof of Principle Study. Inflamm Bowel Dis 2018;24:2468-75. [PMID: 29788410 DOI: 10.1093/ibd/izy151] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
134 Nakamura S, Imaeda H, Nishikawa H, Iimuro M, Matsuura M, Oka H, Oku J, Miyazaki T, Honda H, Watanabe K, Nakase H, Andoh A. Usefulness of fecal calprotectin by monoclonal antibody testing in adult Japanese with inflammatory bowel diseases: a prospective multicenter study. Intest Res 2018;16:554-62. [PMID: 30301337 DOI: 10.5217/ir.2018.00027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
135 Guardiola J, Lobatón T, Cerrillo E, Ferreiro-iglesias R, Gisbert JP, Domènech E, Chaparro M, Esteve M, Rodríguez-moranta F. Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the utility of the determination of faecal calprotectin in inflammatory bowel disease. Gastroenterología y Hepatología (English Edition) 2018;41:514-29. [DOI: 10.1016/j.gastre.2018.05.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
136 Guardiola J, Lobatón T, Cerrillo E, Ferreiro-iglesias R, Gisbert JP, Domènech E, Chaparro M, Esteve M, Rodríguez-moranta F. Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre la utilidad de la determinación de calprotectina fecal en la enfermedad inflamatoria intestinal. Gastroenterología y Hepatología 2018;41:514-29. [DOI: 10.1016/j.gastrohep.2018.05.029] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
137 Genre F, Rueda-Gotor J, Remuzgo-Martínez S, Corrales A, Mijares V, Expósito R, Mata C, Portilla V, Blanco R, Hernández JL, Llorca J, Gualillo O, López-Mejías R, González-Gay MA. Association of circulating calprotectin with lipid profile in axial spondyloarthritis. Sci Rep 2018;8:13728. [PMID: 30213986 DOI: 10.1038/s41598-018-32199-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
138 Goldenberg JZ, Ward L, Day A, Cooley K. Naturopathic Approaches to Irritable Bowel Syndrome-A Delphi Study. J Altern Complement Med 2019;25:227-33. [PMID: 30207740 DOI: 10.1089/acm.2018.0255] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
139 Zhang H, Zeng Z, Mukherjee A, Shen B. Molecular diagnosis and classification of inflammatory bowel disease. Expert Rev Mol Diagn. 2018;18:867-886. [PMID: 30152711 DOI: 10.1080/14737159.2018.1516549] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
140 Kiely CJ, Pavli P, O'Brien CL. The role of inflammation in temporal shifts in the inflammatory bowel disease mucosal microbiome. Gut Microbes 2018;9:477-85. [PMID: 29543557 DOI: 10.1080/19490976.2018.1448742] [Cited by in Crossref: 19] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
141 Schmidlin N, Passweg JR, Halter JP, Heim D, Infanti L, Stern A, Plattner A, Plattner R, Medinger M, Kleber M, Rothen C, Buser A, Bucher C, Holbro A. Baseline calprotectin fails to predict incidence of acute gastrointestinal graft vs. host disease: a prospective study. Bone Marrow Transplant 2019;54:343-7. [PMID: 30108329 DOI: 10.1038/s41409-018-0292-4] [Reference Citation Analysis]
142 Shimoyama T, Yamamoto T, Umegae S, Matsumoto K. Faecal calprotectin level for assessing endoscopic activity and predicting future clinical course in patients with moderately active ulcerative colitis undergoing granulomonocytapheresis: a prospective cohort study. BMC Gastroenterol 2018;18:120. [PMID: 30068300 DOI: 10.1186/s12876-018-0853-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
143 Mccreary DJ, Millman G. Paediatric inflammatory bowel disease: a presenting lesion. Arch Dis Child Educ Pract Ed 2018;103:197-199. [DOI: 10.1136/archdischild-2017-312971] [Reference Citation Analysis]
144 Franklin J. Crohn’s disease. InnovAiT 2018;11:435-442. [DOI: 10.1177/1755738018772321] [Reference Citation Analysis]
145 Hano T, Ito M, Ito K, Uchida M. Sample treatment optimization for fish stool metabolomics. Journal of Chromatography B 2018;1092:258-67. [DOI: 10.1016/j.jchromb.2018.06.014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
146 Kim ES. Optimal Usage of Fecal Calprotectin for Intestinal Diseases. Korean J Med 2018;93:364-368. [DOI: 10.3904/kjm.2018.93.4.364] [Reference Citation Analysis]
147 Dai C, Jiang M, Sun M. Fecal markers in the management of inflammatory bowel disease. Postgraduate Medicine 2018;130:597-606. [DOI: 10.1080/00325481.2018.1503919] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
148 Onişor D, Boeriu A, Pascarenco O, Brusnic O, Dobru D. Role of fecal calprotectin as a biomarker of intestinal inflammation in ulcerative colitis: a prospective study. Revista Romana de Medicina de Laborator 2018;26:335-43. [DOI: 10.2478/rrlm-2018-0006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
149 el Manouni el Hassani S, Berkhout D, Bosch S, Benninga M, de Boer N, de Meij T. Application of Fecal Volatile Organic Compound Analysis in Clinical Practice: Current State and Future Perspectives. Chemosensors 2018;6:29. [DOI: 10.3390/chemosensors6030029] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
150 Dorsey J, Gonska T. Bacterial overgrowth, dysbiosis, inflammation, and dysmotility in the Cystic Fibrosis intestine. J Cyst Fibros 2017;16 Suppl 2:S14-23. [PMID: 28986022 DOI: 10.1016/j.jcf.2017.07.014] [Cited by in Crossref: 52] [Cited by in F6Publishing: 54] [Article Influence: 13.0] [Reference Citation Analysis]
151 Uspenskaya YB, Belogubova SJ. DIAGNOSTIC POSSIBILITIES OF FECAL CALPROTECTIN APPLICATION IN PATIENTS WITH INFLAMMATORY DOWEL DISEASES DURING PREGNANCY (literature review and clinical observations). Koloproktologiâ 2018. [DOI: 10.33878/2073-7556-2018-0-2-95-101] [Reference Citation Analysis]
152 Reenaers C, Bossuyt P, Hindryckx P, Vanpoucke H, Cremer A, Baert F. Expert opinion for use of faecal calprotectin in diagnosis and monitoring of inflammatory bowel disease in daily clinical practice. United European Gastroenterol J 2018;6:1117-25. [PMID: 30288273 DOI: 10.1177/2050640618784046] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 10.3] [Reference Citation Analysis]
153 Kunutsor SK, Flores-Guerrero JL, Kieneker LM, Nilsen T, Hidden C, Sundrehagen E, Seidu S, Dullaart RPF, Bakker SJL. Plasma calprotectin and risk of cardiovascular disease: Findings from the PREVEND prospective cohort study. Atherosclerosis 2018;275:205-13. [PMID: 29957458 DOI: 10.1016/j.atherosclerosis.2018.06.817] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
154 Turvill J, Turnock D, Holmes H, Jones A, Mclaughlan E, Hilton V, Marriott S. Evaluation of the clinical and cost-effectiveness of the York Faecal Calprotectin Care Pathway. Frontline Gastroenterol 2018;9:285-94. [PMID: 30245791 DOI: 10.1136/flgastro-2018-100962] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
155 Holtman GA, Lisman-van Leeuwen Y, van Rheenen PF, Kollen BJ, Escher JC, Kindermann A, de Rijke YB, Berger MY. Evaluation of point-of-care test calprotectin and lactoferrin for inflammatory bowel disease among children with chronic gastrointestinal symptoms. Fam Pract 2017;34:400-6. [PMID: 27535331 DOI: 10.1093/fampra/cmw079] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
156 Medkova A, Srovnal J, Potomkova J, Volejnikova J, Mihal V. Multifarious diagnostic possibilities of the S100 protein family: predominantly in pediatrics and neonatology. World J Pediatr 2018;14:315-21. [PMID: 29858979 DOI: 10.1007/s12519-018-0163-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
157 Geng Q, Zhang QE, Wang F, Zheng W, Ng CH, Ungvari GS, Wang G, Xiang YT. Comparison of comorbid depression between irritable bowel syndrome and inflammatory bowel disease: A meta-analysis of comparative studies. J Affect Disord 2018;237:37-46. [PMID: 29758449 DOI: 10.1016/j.jad.2018.04.111] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
158 Holtman G. Calprotectinetest kan inflammatoire darmziekte veilig uitsluiten. Huisarts Wet 2018;61:29-33. [DOI: 10.1007/s12445-018-0083-6] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
159 Abdelmaksoud A. Peristomal psoriasis: an extraintestinal manifestation of inflammatory bowel disease? Int J Dermatol 2018;57:747-8. [DOI: 10.1111/ijd.13987] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
160 Abdelmaksoud A. Psoriasis/Inflammatory bowel diseases: a time to solve the liaison. J Eur Acad Dermatol Venereol 2018;32:e339-40. [PMID: 29512204 DOI: 10.1111/jdv.14919] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
161 Hassan EA, Ramadan HK, Ismael AA, Mohamed KF, El-Attar MM, Alhelali I. Noninvasive biomarkers as surrogate predictors of clinical and endoscopic remission after infliximab induction in patients with refractory ulcerative colitis. Saudi J Gastroenterol 2017;23:238-45. [PMID: 28721978 DOI: 10.4103/sjg.SJG_599_16] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
162 Heilmann RM, Berghoff N, Mansell J, Grützner N, Parnell NK, Gurtner C, Suchodolski JS, Steiner JM. Association of fecal calprotectin concentrations with disease severity, response to treatment, and other biomarkers in dogs with chronic inflammatory enteropathies. J Vet Intern Med 2018;32:679-92. [PMID: 29460444 DOI: 10.1111/jvim.15065] [Cited by in Crossref: 41] [Cited by in F6Publishing: 47] [Article Influence: 10.3] [Reference Citation Analysis]
163 Yamamoto T, Shimoyama T, Umegae S, Matsumoto K. Endoscopic score vs. fecal biomarkers for predicting relapse in patients with ulcerative colitis after clinical remission and mucosal healing. Clin Transl Gastroenterol 2018;9:136. [PMID: 29491393 DOI: 10.1038/s41424-018-0006-7] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 7.5] [Reference Citation Analysis]
164 Kopylov U, Starr M, Watts C, Dionne S, Girardin M, Seidman EG. Detection of Crohn Disease in Patients with Spondyloarthropathy: The SpACE Capsule Study. J Rheumatol. 2018;45:498-505. [PMID: 29449505 DOI: 10.3899/jrheum.161216] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
165 Gao J, Meyer K, Borucki K, Ueland PM. Multiplex Immuno-MALDI-TOF MS for Targeted Quantification of Protein Biomarkers and Their Proteoforms Related to Inflammation and Renal Dysfunction. Anal Chem 2018;90:3366-73. [DOI: 10.1021/acs.analchem.7b04975] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
166 Broglie L, Rademaker A, Galvin J, Ray A, Tse WT, Duerst R, Schneiderman J, Kletzel M, Chaudhury S. Fecal calprotectin and serum albumin as markers of gastrointestinal graft versus host disease. Hematol Oncol Stem Cell Ther 2018;11:169-74. [PMID: 29397331 DOI: 10.1016/j.hemonc.2017.12.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
167 Derwa Y, Williams CJM, Sood R, Mumtaz S, Bholah MH, Selinger CP, Hamlin PJ, Ford AC, Gracie DJ. Factors affecting clinical decision-making in inflammatory bowel disease and the role of point-of-care calprotectin. Therap Adv Gastroenterol. 2018;11:1756283X17744739. [PMID: 29383026 DOI: 10.1177/1756283x17744739] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
168 Cousins RJ, Liuzzi JP. Trace Metal Absorption and Transport. Physiology of the Gastrointestinal Tract. Elsevier; 2018. pp. 1485-98. [DOI: 10.1016/b978-0-12-809954-4.00061-x] [Cited by in Crossref: 6] [Article Influence: 1.5] [Reference Citation Analysis]
169 Herzlinger M, Cerezo C. Functional Abdominal Pain and Related Syndromes. Child and Adolescent Psychiatric Clinics of North America 2018;27:15-26. [DOI: 10.1016/j.chc.2017.08.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
170 Xu L, Rao P, Liu X, Zeng Z. A New Immunofluorescence Assay for Fecal Calprotectin Distinguishes Inflammatory Bowel Disease from Functional Bowel Disease. OJGas 2018;08:405-414. [DOI: 10.4236/ojgas.2018.811042] [Reference Citation Analysis]
171 Ayling RM, Kok K. Fecal Calprotectin. Adv Clin Chem 2018;87:161-90. [PMID: 30342711 DOI: 10.1016/bs.acc.2018.07.005] [Cited by in Crossref: 70] [Cited by in F6Publishing: 72] [Article Influence: 17.5] [Reference Citation Analysis]
172 Kim Y, Lee M, Gu H, Kim J, Jeong S, Yeo S, Lee YJ, Im S, Sung Y, Kim HJ, Weissman IL, Ahn G. Hypoxia-inducible factor-1 (HIF-1) activation in myeloid cells accelerates DSS-induced colitis progression in mice. Disease Models & Mechanisms. [DOI: 10.1242/dmm.033241] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 4.3] [Reference Citation Analysis]
173 Heida A, Kobold ACM, Wagenmakers L, van de Belt K, van Rheenen PF. Reference values of fecal calgranulin C (S100A12) in school aged children and adolescents. Clin Chem Lab Med 2017;56:126-31. [PMID: 28708568 DOI: 10.1515/cclm-2017-0152] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
174 Horie K, Mikami T, Yoshida T, Sato Y, Okayasu I. Peroxiredoxin 1 expression in active ulcerative colitis mucosa identified by proteome analysis and involvement of thioredoxin based on immunohistochemistry. Oncol Lett 2018;15:2364-72. [PMID: 29434945 DOI: 10.3892/ol.2017.7549] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
175 Ramraj R, Garcia A, Mosen D, Waiwaiole L, Smith N. Utility of Fecal Calprotectin in Evaluation of Chronic Gastrointestinal Symptoms in Primary Care. Clin Pediatr (Phila) 2018;57:1058-63. [PMID: 29192504 DOI: 10.1177/0009922817744607] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
176 Ashton JJ, Harden A, Beattie RM. Paediatric inflammatory bowel disease: improving early diagnosis. Arch Dis Child. 2018;103:307-308. [PMID: 29175974 DOI: 10.1136/archdischild-2017-313955] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
177 Holtman GA, Lisman-van Leeuwen Y, Kollen BJ, Norbruis OF, Escher JC, Kindermann A, de Rijke YB, van Rheenen PF, Berger MY. Diagnostic Accuracy of Fecal Calprotectin for Pediatric Inflammatory Bowel Disease in Primary Care: A Prospective Cohort Study. Ann Fam Med 2016;14:437-45. [PMID: 27621160 DOI: 10.1370/afm.1949] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
178 Teng X, Gao C, Sun M, Wu J. Clinical significance of fecal calprotectin for the early diagnosis of abdominal type of Henoch-Schonlein purpura in children. Clin Rheumatol 2018;37:1667-73. [PMID: 29018973 DOI: 10.1007/s10067-017-3864-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
179 Holtman GA, Lisman-van Leeuwen Y, Day AS, Fagerberg UL, Henderson P, Leach ST, Perminow G, Mack D, van Rheenen PF, van de Vijver E, Wilson DC, Reitsma JB, Berger MY. Use of Laboratory Markers in Addition to Symptoms for Diagnosis of Inflammatory Bowel Disease in Children: A Meta-analysis of Individual Patient Data. JAMA Pediatr 2017;171:984-91. [PMID: 28806445 DOI: 10.1001/jamapediatrics.2017.1736] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
180 Oyaert M, Boel A, Jacobs J, Van den Bremt S, De Sloovere M, Vanpoucke H, Van Hoovels L. Analytical performance and diagnostic accuracy of six different faecal calprotectin assays in inflammatory bowel disease. Clin Chem Lab Med. 2017;55:1564-1573. [PMID: 28222018 DOI: 10.1515/cclm-2016-1012] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 7.6] [Reference Citation Analysis]
181 Lopes S, Andrade P, Rodrigues-Pinto E, Afonso J, Macedo G, Magro F. Fecal marker levels as predictors of need for endoscopic balloon dilation in Crohn’s disease patients with anastomotic strictures. World J Gastroenterol 2017; 23(35): 6482-6490 [PMID: 29085198 DOI: 10.3748/wjg.v23.i35.6482] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
182 Cummins G, Yung DE, Cox BF, Koulaouzidis A, Desmulliez MPY, Cochran S. Luminally expressed gastrointestinal biomarkers. Expert Review of Gastroenterology & Hepatology 2017;11:1119-34. [DOI: 10.1080/17474124.2017.1373017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
183 Whitehead SJ, Ford C, Gama RM, Ali A, Mckaig B, Waldron JL, Steed H, Brookes MJ. Effect of faecal calprotectin assay variability on the management of inflammatory bowel disease and potential role of faecal S100A12. J Clin Pathol 2017;70:1049-56. [DOI: 10.1136/jclinpath-2017-204340] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
184 Harris V, Smith SD. Chronic cheilitis: Faecal calprotectin test a way to diagnose oral Crohn's disease. Australas J Dermatol 2017;58:324-5. [DOI: 10.1111/ajd.12598] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
185 Yamamoto T, Shimoyama T. Monitoring and detection of disease recurrence after resection for Crohn’s disease: the role of non-invasive fecal biomarkers. Expert Review of Gastroenterology & Hepatology 2017;11:899-909. [DOI: 10.1080/17474124.2017.1356226] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
186 Conrad MA, Rosh JR. Pediatric Inflammatory Bowel Disease. Pediatr Clin North Am. 2017;64:577-591. [PMID: 28502439 DOI: 10.1016/j.pcl.2017.01.005] [Cited by in Crossref: 29] [Cited by in F6Publishing: 16] [Article Influence: 5.8] [Reference Citation Analysis]
187 Nakano M, Tominaga K, Hoshino A, Sugaya T, Kanke K, Hiraishi H. Therapeutic efficacy of an elemental diet for patients with crohn's disease and its association with amino acid metabolism. Saudi J Gastroenterol 2017;23:20-7. [PMID: 28139496 DOI: 10.4103/1319-3767.199110] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
188 Lee J. [Fecal Calprotectin in Inflammatory Bowel Disease]. Korean J Gastroenterol 2016;67:233-7. [PMID: 27206433 DOI: 10.4166/kjg.2016.67.5.233] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
189 Yamamoto-furusho J, Bosques-padilla F, Daffra P, De Paula J, Etchevers J, Galiano M, Ibañez P, Juliao F, Kotze P, Marroquín de la Garza J, Monreal Robles R, Rocha J, Steinwurz F, Vázquez-frías R, Veitia G, Zaltman C. Special situations in inflammatory bowel disease: First Latin American consensus of the Pan American Crohn's and Colitis Organisation (PANCCO) (Second part). Revista de Gastroenterología de México (English Edition) 2017;82:134-155. [DOI: 10.1016/j.rgmxen.2016.07.004] [Reference Citation Analysis]
190 Ye L, Zhang YP, Yu N, Jia YX, Wan SJ, Wang FY. Serum platelet factor 4 is a reliable activity parameter in adult patients with inflammatory bowel disease: A pilot study. Medicine (Baltimore) 2017;96:e6323. [PMID: 28296751 DOI: 10.1097/MD.0000000000006323] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
191 Yamamoto-Furusho JK, Bosques-Padilla F, Daffra P, De Paula JA, Etchevers J, Galiano MT, Ibañez P, Juliao F, Kotze PG, Marroquín de la Garza JM, Monreal Robles R, Rocha JL, Steinwurz F, Vázquez-Frías R, Veitia G, Zaltman C. Special situations in inflammatory bowel disease: First Latin American consensus of the Pan American Crohn's and Colitis Organisation (PANCCO) (Second part). Rev Gastroenterol Mex 2017;82:134-55. [PMID: 28318706 DOI: 10.1016/j.rgmx.2016.07.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
192 Manceau H, Chicha-Cattoir V, Puy H, Peoc'h K. Fecal calprotectin in inflammatory bowel diseases: update and perspectives. Clin Chem Lab Med. 2017;55:474-483. [PMID: 27658156 DOI: 10.1515/cclm-2016-0522] [Cited by in Crossref: 56] [Cited by in F6Publishing: 58] [Article Influence: 11.2] [Reference Citation Analysis]
193 Garzón M, Pereira-da-Silva L, Seixas J, Papoila AL, Alves M, Ferreira F, Reis A. Association of enteric parasitic infections with intestinal inflammation and permeability in asymptomatic infants of São Tomé Island. Pathog Glob Health 2017;111:116-27. [PMID: 28279129 DOI: 10.1080/20477724.2017.1299831] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
194 Brookes MJ, Whitehead S, Gaya DR, Hawthorne AB. Practical guidance on the use of faecal calprotectin. Frontline Gastroenterol. 2018;9:87-91. [PMID: 29588834 DOI: 10.1136/flgastro-2016-100762] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
195 Ministro P, Martins D. Fecal biomarkers in inflammatory bowel disease: how, when and why? Expert Rev Gastroenterol Hepatol 2017;11:317-28. [PMID: 28276813 DOI: 10.1080/17474124.2017.1292128] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
196 Pieczarkowski S, Kowalska-duplaga K, Wędrychowicz A, Fyderek K, Kwinta P, Radom A, Zając A, Tomasik P. Calprotectin (S100 A8/A9) and TNF-alpha in differential diagnosis of chronic abdominal pain in children. diagn lab 2017;53:5-10. [DOI: 10.5604/01.3001.0013.7957] [Reference Citation Analysis]
197 El-raouf T. Long Pentraxin PTX 3 and Faecal Calprotectin as a Non Invasive Biomarkers for Ulcerative Colitis. Arch Clin Gastroenterol 2017. [DOI: 10.17352/2455-2283.000030] [Reference Citation Analysis]
198 Kim J, Kim H, Oh HJ, Kim HS, Hwang YJ, Yong D, Jeong SH, Lee K. Fecal Calprotectin Level Reflects the Severity of Clostridium difficile Infection. Ann Lab Med 2017;37:53-7. [PMID: 27834066 DOI: 10.3343/alm.2017.37.1.53] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
199 Siddiqui I, Majid H, Abid S. Update on clinical and research application of fecal biomarkers for gastrointestinal diseases. World J Gastrointest Pharmacol Ther 2017; 8(1): 39-46 [PMID: 28217373 DOI: 10.4292/wjgpt.v8.i1.39] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 34] [Article Influence: 6.8] [Reference Citation Analysis]
200 Aalto K, Lahdenne P, Kolho KL. Fecal calprotectin in juvenile idiopathic arthritis patients related to drug use. Pediatr Rheumatol Online J 2017;15:9. [PMID: 28143478 DOI: 10.1186/s12969-016-0132-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
201 Kochhar G, Lashner B. Utility of Biomarkers in the Management of Inflammatory Bowel Disease. Curr Treat Options Gastroenterol 2017;15:105-15. [PMID: 28138859 DOI: 10.1007/s11938-017-0129-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
202 Strople J, Gold BD. Laboratory Evaluation of Inflammatory Bowel Disease. Pediatric Inflammatory Bowel Disease 2017. [DOI: 10.1007/978-3-319-49215-5_18] [Reference Citation Analysis]
203 Budanur T, Şirin M, Sepet E, Ünür M, Güllüoğlu M, Cantez S, Uğurcan D. Orofacial Crohn’s disease: A case report. Balkan J Dent Med 2017;21:123-126. [DOI: 10.1515/bjdm-2017-0021] [Reference Citation Analysis]
204 Pendsé DA, Makanyanga JC, Plumb AA, Bhatnagar G, Atkinson D, Rodriguez-Justo M, Halligan S, Taylor SA. Diffusion-weighted imaging for evaluating inflammatory activity in Crohn's disease: comparison with histopathology, conventional MRI activity scores, and faecal calprotectin. Abdom Radiol (NY) 2017;42:115-23. [PMID: 27567607 DOI: 10.1007/s00261-016-0863-z] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
205 Damman J, Park KT. Fecal Biomarkers in Inflammatory Bowel Disease. Pediatric Inflammatory Bowel Disease 2017. [DOI: 10.1007/978-3-319-49215-5_19] [Reference Citation Analysis]
206 Flamant M, Roblin X. Laboratory Evaluation, Including Novel Diagnostic Markers. Crohn's Disease and Ulcerative Colitis 2017. [DOI: 10.1007/978-3-319-33703-6_21] [Reference Citation Analysis]
207 Chaudrey KH, Loftus EV. State of the Art and Future Predictions: Isn’t There a Test for That? Diagnosing IBD. Clinical Gastroenterology 2017. [DOI: 10.1007/978-3-319-53763-4_4] [Reference Citation Analysis]
208 Jensen MD, Brodersen JB, Kjeldsen J. Capsule endoscopy for the diagnosis and follow up of Crohn's disease: a comprehensive review of current status. Ann Gastroenterol. 2017;30:168-178. [PMID: 28243037 DOI: 10.20524/aog.2016.0119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
209 Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn's disease. Lancet. 2017;389:1741-1755. [PMID: 27914655 DOI: 10.1016/s0140-6736(16)31711-1] [Cited by in Crossref: 955] [Cited by in F6Publishing: 999] [Article Influence: 159.2] [Reference Citation Analysis]
210 Barnes EL, Burakoff R. New Biomarkers for Diagnosing Inflammatory Bowel Disease and Assessing Treatment Outcomes. Inflamm Bowel Dis 2016;22:2956-65. [PMID: 27763951 DOI: 10.1097/MIB.0000000000000903] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
211 Raman M. Testing for Chronic Diarrhea. Adv Clin Chem 2017;79:199-244. [PMID: 28212712 DOI: 10.1016/bs.acc.2016.09.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
212 Pieczarkowski S, Kowalska-Duplaga K, Kwinta P, Tomasik P, Wędrychowicz A, Fyderek K. Diagnostic Value of Fecal Calprotectin (S100 A8/A9) Test in Children with Chronic Abdominal Pain. Gastroenterol Res Pract 2016;2016:8089217. [PMID: 27974886 DOI: 10.1155/2016/8089217] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
213 Tavabie OD, Hughes SA, Loganayagam A. The role of faecal calprotectin in the differentiation of organic from functional bowel disorders. Br J Gen Pract 2014;64:595-6. [PMID: 25348991 DOI: 10.3399/bjgp14X682525] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
214 Kwapisz L, Mosli M, Chande N, Yan B, Beaton M, Micsko J, Mennill PW, Barnett W, Bax K, Ponich T, Howard J, Tirolese A, Lannigan R, Gregor J. Rapid fecal calprotectin testing to assess for endoscopic disease activity in inflammatory bowel disease: A diagnostic cohort study. Saudi J Gastroenterol 2015;21:360-6. [PMID: 26655130 DOI: 10.4103/1319-3767.170948] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
215 Turina MC, Landewé R, Baeten D. Lessons to be learned from serum biomarkers in psoriasis and IBD – the potential role in SpA. Expert Review of Clinical Immunology 2017;13:333-44. [DOI: 10.1080/1744666x.2017.1244004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
216 Jang HW, Kim HS, Park SJ, Hong SP, Kim TI, Kim WH, Cheon JH. Accuracy of three different fecal calprotectin tests in the diagnosis of inflammatory bowel disease. Intest Res 2016;14:305-13. [PMID: 27799881 DOI: 10.5217/ir.2016.14.4.305] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
217 Mendall MA, Chan D, Patel R, Kumar D. Faecal calprotectin: factors affecting levels and its potential role as a surrogate marker for risk of development of Crohn's Disease. BMC Gastroenterol 2016;16:126. [PMID: 27717310 DOI: 10.1186/s12876-016-0535-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
218 Fernández-bañares F, Accarino A, Balboa A, Domènech E, Esteve M, Garcia-planella E, Guardiola J, Molero X, Rodríguez-luna A, Ruiz-cerulla A, Santos J, Vaquero E. Diarrea crónica: definición, clasificación y diagnóstico. Gastroenterología y Hepatología 2016;39:535-59. [DOI: 10.1016/j.gastrohep.2015.09.018] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
219 Fernández-bañares F, Accarino A, Balboa A, Domènech E, Esteve M, Garcia-planella E, Guardiola J, Molero X, Rodríguez-luna A, Ruiz-cerulla A, Santos J, Vaquero E. Chronic diarrhoea: Definition, classification and diagnosis. Gastroenterología y Hepatología (English Edition) 2016;39:535-59. [DOI: 10.1016/j.gastre.2016.07.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
220 Abej E, El-Matary W, Singh H, Bernstein CN. The Utility of Fecal Calprotectin in the Real-World Clinical Care of Patients with Inflammatory Bowel Disease. Can J Gastroenterol Hepatol 2016;2016:2483261. [PMID: 27774443 DOI: 10.1155/2016/2483261] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
221 Özşeker B, Şahin C, Özşeker HS, Efe SC, Kav T, Bayraktar Y. The Role of Fecal Calprotectin in Evaluating Intestinal Involvement of Behçet's Disease. Dis Markers 2016;2016:5423043. [PMID: 27642216 DOI: 10.1155/2016/5423043] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
222 Chatzikonstantinou M, Konstantopoulos P, Stergiopoulos S, Kontzoglou K, Verikokos C, Perrea D, Dimitroulis D. Calprotectin as a diagnostic tool for inflammatory bowel diseases. Biomed Rep 2016;5:403-7. [PMID: 27699005 DOI: 10.3892/br.2016.751] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
223 Abdalla SM, Kalra G, Moshiree B. Motility Evaluation in the Patient with Inflammatory Bowel Disease. Gastrointest Endosc Clin N Am. 2016;26:719-738. [PMID: 27633599 DOI: 10.1016/j.giec.2016.06.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
224 Auth MK. The diagnostic accuracy of faecal calprotectin in investigations for suspected inflammatory bowel disease in children. Br J Gen Pract 2015;65:628-9. [PMID: 26622015 DOI: 10.3399/bjgp15X687769] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
225 Iborra M, Beltrán B, Nos P. Noninvasive Testing for Mucosal Inflammation in Inflammatory Bowel Disease. Gastrointest Endosc Clin N Am 2016;26:641-56. [PMID: 27633593 DOI: 10.1016/j.giec.2016.06.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
226 Deda O, Chatziioannou AC, Fasoula S, Palachanis D, Raikos Ν, Theodoridis GA, Gika HG. Sample preparation optimization in fecal metabolic profiling. J Chromatogr B Analyt Technol Biomed Life Sci 2017;1047:115-23. [PMID: 27423778 DOI: 10.1016/j.jchromb.2016.06.047] [Cited by in Crossref: 53] [Cited by in F6Publishing: 55] [Article Influence: 8.8] [Reference Citation Analysis]
227 Melchior C, Aziz M, Aubry T, Gourcerol G, Quillard M, Zalar A, Coëffier M, Dechelotte P, Leroi AM, Ducrotté P. Does calprotectin level identify a subgroup among patients suffering from irritable bowel syndrome? Results of a prospective study. United European Gastroenterol J 2017;5:261-9. [PMID: 28344794 DOI: 10.1177/2050640616650062] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
228 Peretz A, Tkhawkho L, Pastukh N, Brodsky D, Halevi CN, Nitzan O. Correlation between fecal calprotectin levels, disease severity and the hypervirulent ribotype 027 strain in patients with Clostridium difficile infection. BMC Infect Dis. 2016;16:309. [PMID: 27334992 DOI: 10.1186/s12879-016-1618-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
229 Moller FT, Knudsen L, Harbord M, Satsangi J, Gordon H, Christiansen L, Christensen K, Jess T, Andersen V. Danish cohort of monozygotic inflammatory bowel disease twins: Clinical characteristics and inflammatory activity. World J Gastroenterol 2016; 22(21): 5050-5059 [PMID: 27275097 DOI: 10.3748/wjg.v22.i21.5050] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
230 McFarlane M, Chambers S, Malik A, Lee B, Sung E, Nwokolo C, Waugh N, Arasaradnam R. Clinical outcomes at 12 months and risk of inflammatory bowel disease in patients with an intermediate raised fecal calprotectin: a 'real-world' view. BMJ Open 2016;6:e011041. [PMID: 27266773 DOI: 10.1136/bmjopen-2016-011041] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
231 Turvill J, Aghahoseini A, Sivarajasingham N, Abbas K, Choudhry M, Polyzois K, Lasithiotakis K, Volanaki D, Kim B, Langlands F, Andrew H, Roos J, Mellen S, Turnock D, Jones A. Faecal calprotectin in patients with suspected colorectal cancer: a diagnostic accuracy study. Br J Gen Pract 2016;66:e499-506. [PMID: 27266863 DOI: 10.3399/bjgp16X685645] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 6.3] [Reference Citation Analysis]
232 Elsaadany HM, Almaghraby MF, Edrees AA, Elsherbiny YM, Kumar RK. Utility of fecal calprotectin as a discriminative biomarker between ulcerative colitis and irritable bowel syndrome and its ability to be used for the assessment of the remission stage of ulcerative colitis. Egypt J Intern Med 2016;28:21-7. [DOI: 10.4103/1110-7782.182956] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
233 Basirat V, Azizi Z, Javid Anbardan S, Taghizadeh Asl M, Farbod Y, Teimouri A, Ebrahimi Daryani N. Accuracy of 99mTc (V)-Dimercaptosuccinic Acid Scintigraphy and Fecal Calprotectin Compared with Colonoscopy in Localizing Active Lesions in Inflammatory Bowel Disease. Middle East J Dig Dis 2016;8:212-218. [DOI: 10.15171/mejdd.2016.23] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
234 Prata MM, Havt A, Bolick DT, Pinkerton R, Lima A, Guerrant RL. Comparisons between myeloperoxidase, lactoferrin, calprotectin and lipocalin-2, as fecal biomarkers of intestinal inflammation in malnourished children. J Transl Sci 2016;2:134-9. [PMID: 27746954 DOI: 10.15761/JTS.1000130] [Cited by in Crossref: 8] [Cited by in F6Publishing: 25] [Article Influence: 1.3] [Reference Citation Analysis]
235 Rogler G, Biedermann L. Clinical Utility of Biomarkers in IBD. Curr Gastroenterol Rep. 2015;17:26. [PMID: 26122247 DOI: 10.1007/s11894-015-0449-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
236 Alibrahim B, Aljasser MI, Salh B. Fecal calprotectin use in inflammatory bowel disease and beyond: A mini-review. Can J Gastroenterol Hepatol 2015;29:157-63. [PMID: 25855880 DOI: 10.1155/2015/950286] [Cited by in Crossref: 45] [Cited by in F6Publishing: 48] [Article Influence: 7.5] [Reference Citation Analysis]
237 Turvill J, O’connell S, Brooks A, Bradley-wood K, Laing J, Thiagarajan S, Hammond D, Turnock D, Jones A, Sood R, Ford A. Evaluation of a faecal calprotectin care pathway for use in primary care. Prim Health Care Res Dev 2016;17:428-36. [DOI: 10.1017/s1463423616000049] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
238 Kucharski M, Karczewski J, Mańkowska-Wierzbicka D, Karmelita-Katulska K, Kaczmarek E, Iwanik K, Rzymski P, Grzymisławski M, Linke K, Dobrowolska A. Usefulness of Endoscopic Indices in Determination of Disease Activity in Patients with Crohn's Disease. Gastroenterol Res Pract 2016;2016:7896478. [PMID: 26997952 DOI: 10.1155/2016/7896478] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
239 Ikhtaire S, Shajib MS, Reinisch W, Khan WI. Fecal calprotectin: Its scope and utility in the management of inflammatory bowel disease. J Gastroenterol. 2016;51:434-446. [PMID: 26897740 DOI: 10.1007/s00535-016-1182-4] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 8.0] [Reference Citation Analysis]
240 Okuyama Y, Doi Y, Matsuyama N, Uchino M, Yamamoto T. A novel sol particle immunoassay for fecal calprotectin in inflammatory bowel disease patients. Clin Chim Acta 2016;456:1-6. [PMID: 26908083 DOI: 10.1016/j.cca.2016.02.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
241 Radillo O, Pascolo L, Martelossi S, Dal Bo S, Ventura A. Fecal Calprotectin: Diagnostic Accuracy of the Immunochromatographic CalFast Assay in a Pediatric Population. J Clin Lab Anal 2016;30:500-5. [PMID: 26879689 DOI: 10.1002/jcla.21886] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
242 Liu Y, Zhong LP. Reply to "Accuracy of diagnosis of salivary gland tumors with the use of ultrasonography, computed tomography, and magnetic resonance imaging: a meta-analysis--a commentary". Oral Surg Oral Med Oral Pathol Oral Radiol 2016;121:341-3. [PMID: 26868472 DOI: 10.1016/j.oooo.2015.11.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
243 Soubières AA, Poullis A. Emerging role of novel biomarkers in the diagnosis of inflammatory bowel disease. World J Gastrointest Pharmacol Ther 2016; 7(1): 41-50 [PMID: 26855811 DOI: 10.4292/wjgpt.v7.i1.41] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 35] [Article Influence: 5.5] [Reference Citation Analysis]
244 Saha A, Tighe MP, Batra A. How to use faecal calprotectin in management of paediatric inflammatory bowel disease. Arch Dis Child Educ Pract Ed 2016;101:124-8. [DOI: 10.1136/archdischild-2014-307941] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
245 Walsham NE, Sherwood RA. Fecal calprotectin in inflammatory bowel disease. Clin Exp Gastroenterol. 2016;9:21-29. [PMID: 26869808 DOI: 10.2147/ceg.s51902] [Cited by in Crossref: 37] [Cited by in F6Publishing: 68] [Article Influence: 6.2] [Reference Citation Analysis]
246 Ikonomi E, Rothstein RD, Ehrlich AC, Friedenberg FK. Measurement of Fractional Exhaled Nitric Oxide as a Marker of Disease Activity in Inflammatory Bowel Disease. J Gastroenterol Pancreatol Liver Disord 2016;3. [PMID: 27398403 DOI: 10.15226/2374-815X/3/1/00146] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
247 Higuchi LM, Regan BP, Bousvaros A. Ulcerative Colitis. Textbook of Pediatric Gastroenterology, Hepatology and Nutrition 2016. [DOI: 10.1007/978-3-319-17169-2_30] [Reference Citation Analysis]
248 Philp MM, Ross HM. IBD Diagnosis and Evaluation. The ASCRS Textbook of Colon and Rectal Surgery 2016. [DOI: 10.1007/978-3-319-25970-3_45] [Reference Citation Analysis]
249 Sandborn WJ, Panés J, Zhang H, Yu D, Niezychowski W, Su C. Correlation Between Concentrations of Fecal Calprotectin and Outcomes of Patients With Ulcerative Colitis in a Phase 2 Trial. Gastroenterology 2016;150:96-102. [PMID: 26376350 DOI: 10.1053/j.gastro.2015.09.001] [Cited by in Crossref: 72] [Cited by in F6Publishing: 75] [Article Influence: 12.0] [Reference Citation Analysis]
250 Burisch J, Munkholm P. Telemonitoring and Self-Care in Patients with IBD. Telemanagement of Inflammatory Bowel Disease 2016. [DOI: 10.1007/978-3-319-22285-1_7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
251 Holtman GA, Lisman-van Leeuwen Y, Reitsma JB, Berger MY. Noninvasive Tests for Inflammatory Bowel Disease: A Meta-analysis. Pediatrics 2016;137. [PMID: 26681783 DOI: 10.1542/peds.2015-2126] [Cited by in Crossref: 40] [Cited by in F6Publishing: 45] [Article Influence: 6.7] [Reference Citation Analysis]
252 Cypers H, Varkas G, Beeckman S, Debusschere K, Vogl T, Roth J, Drennan MB, Lavric M, Foell D, Cuvelier CA, De Vos M, Delanghe J, Van den Bosch F, Elewaut D. Elevated calprotectin levels reveal bowel inflammation in spondyloarthritis. Ann Rheum Dis. 2016;75:1357-1362. [PMID: 26698844 DOI: 10.1136/annrheumdis-2015-208025] [Cited by in Crossref: 65] [Cited by in F6Publishing: 66] [Article Influence: 9.3] [Reference Citation Analysis]
253 Goutorbe F, Goutte M, Minet-Quinard R, Boucher AL, Pereira B, Bommelaer G, Buisson A. Endoscopic Factors Influencing Fecal Calprotectin Value in Crohn's Disease. J Crohns Colitis 2015;9:1113-9. [PMID: 26351383 DOI: 10.1093/ecco-jcc/jjv150] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
254 Barnes EL, Liew CC, Chao S, Burakoff R. Use of blood based biomarkers in the evaluation of Crohn’s disease and ulcerative colitis. World J Gastrointest Endosc 2015; 7(17): 1233-1237 [PMID: 26634038 DOI: 10.4253/wjge.v7.i17.1233] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
255 Benítez JM, García-Sánchez V. Faecal calprotectin: Management in inflammatory bowel disease. World J Gastrointest Pathophysiol 2015; 6(4): 203-209 [PMID: 26600978 DOI: 10.4291/wjgp.v6.i4.203] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
256 Melinder C, Hiyoshi A, Hussein O, Halfvarson J, Ekbom A, Montgomery S. Physical Fitness in Adolescence and Subsequent Inflammatory Bowel Disease Risk. Clin Transl Gastroenterol. 2015;6:e121. [PMID: 26540026 DOI: 10.1038/ctg.2015.49] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
257 Delefortrie Q, Schatt P, Grimmelprez A, Gohy P, Deltour D, Collard G, Vankerkhoven P. Comparison of the Liaison® Calprotectin kit with a well established point of care test (Quantum Blue - Bühlmann-Alere®) in terms of analytical performances and ability to detect relapses amongst a Crohn population in follow-up. Clin Biochem 2016;49:268-73. [PMID: 26506117 DOI: 10.1016/j.clinbiochem.2015.10.010] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
258 Sands BE. Biomarkers of Inflammation in Inflammatory Bowel Disease. Gastroenterology 2015;149:1275-1285.e2. [PMID: 26166315 DOI: 10.1053/j.gastro.2015.07.003] [Cited by in Crossref: 205] [Cited by in F6Publishing: 213] [Article Influence: 29.3] [Reference Citation Analysis]
259 mal. Fäkale Marker unterstützen Diagnostik. CME 2015;12:19-19. [DOI: 10.1007/s11298-015-1394-6] [Reference Citation Analysis]
260 Bressler B, Panaccione R, Fedorak RN, Seidman EG. Clinicians’ guide to the use of fecal calprotectin to identify and monitor disease activity in inflammatory bowel disease. Can J Gastroenterol Hepatol. 2015;29:369-372. [PMID: 26125109 DOI: 10.1155/2015/852723] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 6.4] [Reference Citation Analysis]
261 Heida A, Dijkstra A, Groen H, Muller Kobold A, Verkade H, van Rheenen P. Comparing the efficacy of a web-assisted calprotectin-based treatment algorithm (IBD-live) with usual practices in teenagers with inflammatory bowel disease: study protocol for a randomized controlled trial. Trials 2015;16:271. [PMID: 26073770 DOI: 10.1186/s13063-015-0787-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
262 Soto-Méndez MJ, Romero-Abal ME, Aguilera CM, Rico MC, Solomons NW, Schümann K, Gil A. Associations among Inflammatory Biomarkers in the Circulating, Plasmatic, Salivary and Intraluminal Anatomical Compartments in Apparently Healthy Preschool Children from the Western Highlands of Guatemala. PLoS One 2015;10:e0129158. [PMID: 26075910 DOI: 10.1371/journal.pone.0129158] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
263 Mitselos IV, Christodoulou DK, Katsanos KH, Tsianos EV. Role of wireless capsule endoscopy in the follow-up of inflammatory bowel disease. World J Gastrointest Endosc 2015; 7(6): 643-651 [PMID: 26078832 DOI: 10.4253/wjge.v7.i6.643] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
264 George CM, Oldja L, Biswas SK, Perin J, Lee GO, Ahmed S, Haque R, Sack RB, Parvin T, Azmi IJ, Bhuyian SI, Talukder KA, Faruque AG. Fecal Markers of Environmental Enteropathy are Associated with Animal Exposure and Caregiver Hygiene in Bangladesh. Am J Trop Med Hyg 2015;93:269-75. [PMID: 26055734 DOI: 10.4269/ajtmh.14-0694] [Cited by in Crossref: 78] [Cited by in F6Publishing: 81] [Article Influence: 11.1] [Reference Citation Analysis]
265 Jiang W, Li X. Molecular Analysis of Inflammatory Bowel Disease: Clinically Useful Tools for Diagnosis, Response Prediction, and Monitoring of Targeted Therapy. Mol Diagn Ther 2015;19:141-58. [DOI: 10.1007/s40291-015-0142-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
266 Kalantari H, Taheri A, Yaran M. Fecal calprotectin is a useful marker to diagnose ulcerative colitis from irritable bowel syndrome. Adv Biomed Res. 2015;4:85. [PMID: 26015911 DOI: 10.4103/2277-9175.156647] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
267 Wright EK, Kamm MA, De Cruz P, Hamilton AL, Ritchie KJ, Krejany EO, Leach S, Gorelik A, Liew D, Prideaux L, Lawrance IC, Andrews JM, Bampton PA, Jakobovits SL, Florin TH, Gibson PR, Debinski H, Macrae FA, Samuel D, Kronborg I, Radford-Smith G, Selby W, Johnston MJ, Woods R, Elliott PR, Bell SJ, Brown SJ, Connell WR, Day AS, Desmond PV, Gearry RB. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn's disease after surgery. Gastroenterology 2015;148:938-947.e1. [PMID: 25620670 DOI: 10.1053/j.gastro.2015.01.026] [Cited by in Crossref: 195] [Cited by in F6Publishing: 203] [Article Influence: 27.9] [Reference Citation Analysis]
268 George CM, Oldja L, Biswas S, Perin J, Lee GO, Kosek M, Sack RB, Ahmed S, Haque R, Parvin T, Azmi IJ, Bhuyian SI, Talukder KA, Mohammad S, Faruque AG. Geophagy is associated with environmental enteropathy and stunting in children in rural Bangladesh. Am J Trop Med Hyg 2015;92:1117-24. [PMID: 25918214 DOI: 10.4269/ajtmh.14-0672] [Cited by in Crossref: 92] [Cited by in F6Publishing: 102] [Article Influence: 13.1] [Reference Citation Analysis]
269 Stawczyk-Eder K, Eder P, Lykowska-Szuber L, Krela-Kazmierczak I, Klimczak K, Szymczak A, Szachta P, Katulska K, Linke K. Is faecal calprotectin equally useful in all Crohn’s disease locations? A prospective, comparative study. Arch Med Sci. 2015;11:353-361. [PMID: 25995752 DOI: 10.5114/aoms.2014.43672] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 4.1] [Reference Citation Analysis]
270 Koulaouzidis A, Nemeth A, Johansson GW, Toth E. Dissecting Lewis score under the light of fecal calprotectin; an analysis of correlation of score components with calprotectin levels in capsule endoscopy. Ann Gastroenterol 2015;28:259-64. [PMID: 25830236] [Reference Citation Analysis]
271 Hasler S, Zahnd N, Müller S, Vavricka S, Rogler G, Tandjung R, Rosemann T. VAlidation of an 8-item-questionnaire predictive for a positive caLprotectin tEst and Real-life implemenTation in primary care to reduce diagnostic delay in inflammatory bowel disease (ALERT): protocol for a prospective diagnostic study. BMJ Open. 2015;5:e007306. [PMID: 25757949 DOI: 10.1136/bmjopen-2014-007306] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
272 Vincent Z, Hornby S, Ball S, Sanders G, Ayling RM. Faecal calprotectin as a marker for oesophago-gastric cancer. Ann Clin Biochem 2015;52:660-4. [DOI: 10.1177/0004563215578191] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
273 Abildtrup M, Kingsley GH, Scott DL. Calprotectin as a biomarker for rheumatoid arthritis: a systematic review. J Rheumatol 2015;42:760-70. [PMID: 25729036 DOI: 10.3899/jrheum.140628] [Cited by in Crossref: 64] [Cited by in F6Publishing: 69] [Article Influence: 9.1] [Reference Citation Analysis]
274 Maconi G, Magro F. Comparing techniques to achieve high accuracy and low cost: how should we first diagnose Crohn's disease? Journal of Comparative Effectiveness Research 2015;4:75-8. [DOI: 10.2217/cer.15.2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
275 Karczewski J, Swora-Cwynar E, Rzymski P, Poniedziałek B, Adamski Z. Selected biologic markers of inflammation and activity of Crohn's disease. Autoimmunity 2015;48:318-27. [PMID: 25707687 DOI: 10.3109/08916934.2015.1016221] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
276 Bodewes FA, Verkade HJ, Taminiau JA, Borowitz D, Wilschanski M; Working group C​ystic Fibrosis and Pancreatic Disease of the European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN). Cystic fibrosis and the role of gastrointestinal outcome measures in the new era of therapeutic CFTR modulation. J Cyst Fibros 2015;14:169-77. [PMID: 25677689 DOI: 10.1016/j.jcf.2015.01.006] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 5.4] [Reference Citation Analysis]
277 Lehmann FS, Burri E, Beglinger C. The role and utility of faecal markers in inflammatory bowel disease. Therap Adv Gastroenterol. 2015;8:23-36. [PMID: 25553077 DOI: 10.1177/1756283x14553384] [Cited by in Crossref: 104] [Cited by in F6Publishing: 109] [Article Influence: 14.9] [Reference Citation Analysis]
278 Cauchi M, Fowler DP, Walton C, Turner C, Waring RH, Ramsden DB, Hunter JO, Teale P, Cole JA, Bessant C. Comparison of GC-MS, HPLC-MS and SIFT-MS in conjunction with multivariate classification for the diagnosis of Crohn's disease in urine. Anal Methods 2015;7:8379-85. [DOI: 10.1039/c5ay01322d] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
279 Osipenko MF, Livzan MA, Skalinskaya MI, Lyalyukova EA. Fecal calprotectin concentration in the differential diagnosis of bowel diseases. Ter arkh 2015;87:30. [DOI: 10.17116/terarkh201587230-33] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
280 Card TR, Siffledeen J, Fleming KM. Are IBD patients more likely to have a prior diagnosis of irritable bowel syndrome? Report of a case-control study in the General Practice Research Database. United European Gastroenterol J 2014;2:505-12. [PMID: 25452846 DOI: 10.1177/2050640614554217] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 4.3] [Reference Citation Analysis]
281 Mosli M, Al Beshir M, Al-Judaibi B, Al-Ameel T, Saleem A, Bessissow T, Ghosh S, Almadi M. Advances in the diagnosis and management of inflammatory bowel disease: challenges and uncertainties. Saudi J Gastroenterol 2014;20:81-101. [PMID: 24705146 DOI: 10.4103/1319-3767.129473] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
282 Shivaji UN, Ford AC. Beliefs about management of irritable bowel syndrome in primary care: cross-sectional survey in one locality. Prim Health Care Res Dev 2015;16:263-9. [DOI: 10.1017/s1463423614000383] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
283 Oyaert M, Trouvé C, Baert F, De Smet D, Langlois M, Vanpoucke H. Comparison of two immunoassays for measurement of faecal calprotectin in detection of inflammatory bowel disease: (pre)-analytical and diagnostic performance characteristics. Clin Chem Lab Med. 2014;52:391-397. [PMID: 24114912 DOI: 10.1515/cclm-2013-0699] [Cited by in Crossref: 32] [Cited by in F6Publishing: 37] [Article Influence: 4.0] [Reference Citation Analysis]
284 Naismith GD, Smith LA, Barry SJ, Munro JI, Laird S, Rankin K, Morris AJ, Winter JW, Gaya DR. A prospective evaluation of the predictive value of faecal calprotectin in quiescent Crohn's disease. Journal of Crohn's and Colitis 2014;8:1022-9. [DOI: 10.1016/j.crohns.2014.01.029] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 4.4] [Reference Citation Analysis]
285 Seenan JP, Thomson F, Rankin K, Smith K, Gaya DR. Are we exposing patients with a mildly elevated faecal calprotectin to unnecessary investigations? Frontline Gastroenterol 2015;6:156-60. [PMID: 28839805 DOI: 10.1136/flgastro-2014-100467] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
286 Labaere D, Smismans A, Van Olmen A, Christiaens P, D'Haens G, Moons V, Cuyle PJ, Frans J, Bossuyt P. Comparison of six different calprotectin assays for the assessment of inflammatory bowel disease. United European Gastroenterol J. 2014;2:30-37. [PMID: 24918006 DOI: 10.1177/2050640613518201] [Cited by in Crossref: 101] [Cited by in F6Publishing: 104] [Article Influence: 12.6] [Reference Citation Analysis]
287 Dhar A. Faecal calprotectin-ready for prime time? Frontline Gastroenterol 2015;6:11-3. [PMID: 28839789 DOI: 10.1136/flgastro-2014-100477] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
288 Goepp J, Fowler E, McBride T, Landis D. Frequency of abnormal fecal biomarkers in irritable bowel syndrome. Glob Adv Health Med. 2014;3:9-15. [PMID: 24891989 DOI: 10.7453/gahmj.2013.099] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
289 Parsons K, Goepp J, Dechairo B, Fowler E, Markward N, Hanaway P, McBride T, Landis D. Novel Testing Enhances Irritable Bowel Syndrome Medical Management: The IMMINENT Study. Glob Adv Health Med 2014;3:25-32. [PMID: 24891991 DOI: 10.7453/gahmj.2013.100] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
290 Fengming Y, Jianbing W. Biomarkers of inflammatory bowel disease. Dis Markers. 2014;2014:710915. [PMID: 24963213 DOI: 10.1155/2014/710915] [Cited by in Crossref: 53] [Cited by in F6Publishing: 60] [Article Influence: 6.6] [Reference Citation Analysis]
291 Misra S, Barth JH. How good is the evidence base for test selection in clinical guidelines? Clinica Chimica Acta 2014;432:27-32. [DOI: 10.1016/j.cca.2014.01.040] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
292 Banerjee A, Srinivas M, Eyre R, Ellis R, Waugh N, Bardhan KD, Basumani P. Faecal calprotectin for differentiating between irritable bowel syndrome and inflammatory bowel disease: a useful screen in daily gastroenterology practice. Frontline Gastroenterol. 2015;6:20-26. [PMID: 28839790 DOI: 10.1136/flgastro-2013-100429] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
293 Burri E, Manz M, Schroeder P, Froehlich F, Rossi L, Beglinger C, Lehmann FS. Diagnostic yield of endoscopy in patients with abdominal complaints: incremental value of faecal calprotectin on guidelines of appropriateness. BMC Gastroenterol 2014;14:57. [PMID: 24679065 DOI: 10.1186/1471-230X-14-57] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
294 Shepherd SF, McGuire ND, de Lacy Costello BP, Ewen RJ, Jayasena DH, Vaughan K, Ahmed I, Probert CS, Ratcliffe NM. The use of a gas chromatograph coupled to a metal oxide sensor for rapid assessment of stool samples from irritable bowel syndrome and inflammatory bowel disease patients. J Breath Res. 2014;8:026001. [PMID: 24674940 DOI: 10.1088/1752-7155/8/2/026001] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
295 Pasanen ME. Evaluation and treatment of colonic symptoms. Med Clin North Am 2014;98:529-47. [PMID: 24758959 DOI: 10.1016/j.mcna.2014.01.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
296 Dhaliwal A, Zeino Z, Tomkins C, Cheung M, Nwokolo C, Smith S, Harmston C, Arasaradnam RP. Utility of faecal calprotectin in inflammatory bowel disease (IBD): what cut-offs should we apply? Frontline Gastroenterol. 2015;6:14-19. [PMID: 25580205 DOI: 10.1136/flgastro-2013-100420] [Cited by in Crossref: 61] [Cited by in F6Publishing: 65] [Article Influence: 7.6] [Reference Citation Analysis]
297 August KJ, Chiang KY, Qayed M, Dulson A, Worthington-White D, Cole CR, Horan JT. Relative defects in mucosal immunity predict acute graft-versus-host disease. Biol Blood Marrow Transplant 2014;20:1056-9. [PMID: 24641826 DOI: 10.1016/j.bbmt.2014.03.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
298 Montagnana M, Danese E, Lippi G. Calprotectin and cardiovascular events. A narrative review. Clin Biochem 2014;47:996-1001. [PMID: 24625561 DOI: 10.1016/j.clinbiochem.2014.02.021] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
299 Nilsen T, Sundström J, Lind L, Larsson A. Serum calprotectin levels in elderly males and females without bacterial or viral infections. Clin Biochem 2014;47:1065-8. [PMID: 24440500 DOI: 10.1016/j.clinbiochem.2014.01.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
300 Däbritz J, Musci J, Foell D. Diagnostic utility of faecal biomarkers in patients with irritable bowel syndrome. World J Gastroenterol 2014; 20(2): 363-375 [PMID: 24574706 DOI: 10.3748/wjg.v20.i2.363] [Cited by in CrossRef: 46] [Cited by in F6Publishing: 48] [Article Influence: 5.8] [Reference Citation Analysis]
301 Hong SN. [The usefulness of fecal calprotectin in differentiating between functional and organic bowel diseases: application in pediatric constipation patients]. Korean J Gastroenterol 2013;62:261-2. [PMID: 24404647 DOI: 10.4166/kjg.2013.62.5.261] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
302 Roblin X, Cavaille A, Clavel L, Paul S. Intérêt des biomarqueurs dans la prise en charge des MICI. La Presse Médicale 2014;43:66-73. [DOI: 10.1016/j.lpm.2013.11.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
303 Pal A. Crohn's disease. InnovAiT 2014;7:43-54. [DOI: 10.1177/1755738013512118] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
304 Friedman A, Gibson P. Inflammatory Bowel Disease – Crohn's Disease and Ulcerative Colitis. Reference Module in Biomedical Sciences. Elsevier; 2014. [DOI: 10.1016/b978-0-12-801238-3.00052-0] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
305 Holtman GA, Lisman-van Leeuwen Y, Kollen BJ, Escher JC, Kindermann A, Rheenen PF, Berger MY. Challenges in diagnostic accuracy studies in primary care: the fecal calprotectin example. BMC Fam Pract 2013;14:179. [PMID: 24274463 DOI: 10.1186/1471-2296-14-179] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
306 Mosli M, Fahmy M, Garg SK, Feagan SG, Baker KA, Zou G, Macdonald JK, Sandborn WJ, Chande N; Cochrane IBD Group. Biomarkers for assessing disease activity in inflammatory bowel disease. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd010848] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
307 Moniuszko A, Wiśniewska A, Rydzewska G. Biomarkers in management of inflammatory bowel disease. Prz Gastroenterol. 2013;8:275-283. [PMID: 24868269 DOI: 10.5114/pg.2013.38728] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
308 Albers R, Bourdet-Sicard R, Braun D, Calder PC, Herz U, Lambert C, Lenoir-Wijnkoop I, Méheust A, Ouwehand A, Phothirath P, Sako T, Salminen S, Siemensma A, van Loveren H, Sack U. Monitoring immune modulation by nutrition in the general population: identifying and substantiating effects on human health. Br J Nutr 2013;110 Suppl 2:S1-30. [PMID: 23902657 DOI: 10.1017/S0007114513001505] [Cited by in Crossref: 73] [Cited by in F6Publishing: 77] [Article Influence: 8.1] [Reference Citation Analysis]
309 Vaos G, Kostakis ID, Zavras N, Chatzemichael A. The role of calprotectin in pediatric disease. Biomed Res Int 2013;2013:542363. [PMID: 24175291 DOI: 10.1155/2013/542363] [Cited by in Crossref: 42] [Cited by in F6Publishing: 46] [Article Influence: 4.7] [Reference Citation Analysis]
310 Yamagami H, Watanabe K, Kamata N, Sogawa M, Arakawa T. Small bowel endoscopy in inflammatory bowel disease. Clin Endosc. 2013;46:321-326. [PMID: 23964328 DOI: 10.5946/ce.2013.46.4.321] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
311 Kocna P, Vanickova Z, Zima T. Laboratory screening markers in gastroenterology - state of the art. BIOMED PAP 2013;157:91-97. [DOI: 10.5507/bp.2013.027] [Reference Citation Analysis]
312 Rodríguez-moranta F, Lobatón T, Rodríguez-alonso L, Guardiola J. Calprotectina fecal en el diagnóstico de enfermedades inflamatorias. Gastroenterología y Hepatología 2013;36:400-6. [DOI: 10.1016/j.gastrohep.2012.10.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
313 Marcuzzi A, Bianco AM, Girardelli M, Tommasini A, Martelossi S, Monasta L, Crovella S. Genetic and functional profiling of Crohn's disease: autophagy mechanism and susceptibility to infectious diseases. Biomed Res Int 2013;2013:297501. [PMID: 23738324 DOI: 10.1155/2013/297501] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
314 Burri E, Schulte F, Muser J, Meier R, Beglinger C. Measurement of calprotectin in ascitic fluid to identify elevated polymorphonuclear cell count. World J Gastroenterol 2013; 19(13): 2028-2036 [PMID: 23599621 DOI: 10.3748/wjg.v19.i13.2028] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
315 Webber EC. Fecal Calprotectin to Screen for IBD? AAP Grand Rounds 2013;29:38-38. [DOI: 10.1542/gr.29-4-38] [Reference Citation Analysis]
316 Medina E. Enfermedad inflamatoria intestinal (II): diagnóstico y tratamiento. Anales de Pediatría Continuada 2013;11:68-78. [DOI: 10.1016/s1696-2818(13)70121-5] [Reference Citation Analysis]
317 Caccaro R, D'Incà R, Pathak S, Sturniolo GC. Clinical utility of calprotectin and lactoferrin in patients with inflammatory bowel disease: is there something new from the literature? Expert Rev Clin Immunol 2012;8:579-85. [PMID: 22992152 DOI: 10.1586/eci.12.50] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
318 Hernández Z, Almeida P, Borrego L, Hernández J. Infiltrated perianal plaques. Perianal Crohn's disease. Int J Dermatol 2013;52:23-4. [PMID: 23278605 DOI: 10.1111/j.1365-4632.2012.05540.x] [Reference Citation Analysis]
319 Lee K. Fecal Biomarkers in Inflammatory Bowel Disease. Intest Res 2013;11:73. [DOI: 10.5217/ir.2013.11.2.73] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
320 C. Ferri's Clinical Advisor 2013 2013. [DOI: 10.1016/b978-0-323-08373-7.00012-1] [Reference Citation Analysis]
321 Strople J, Gold BD. Laboratory Evaluation of Inflammatory Bowel Disease. Pediatric Inflammatory Bowel Disease 2013. [DOI: 10.1007/978-1-4614-5061-0_18] [Reference Citation Analysis]
322 U. Ferri's Clinical Advisor 2013 2013. [DOI: 10.1016/b978-0-323-08373-7.00030-3] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
323 Smith LA, Gaya DR. Utility of faecal calprotectin analysis in adult inflammatory bowel disease. World J Gastroenterol 2012; 18(46): 6782-6789 [PMID: 23239916 DOI: 10.3748/wjg.v18.i46.6782] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 46] [Article Influence: 4.3] [Reference Citation Analysis]
324 Holtman G, Lisman-van Leeuwen Y, van Rheenen P, Berger M. Kinderen met chronische gastro-intestinale klachten. HUISARTS WETENSCHAP 2012;55:562-563. [DOI: 10.1007/s12445-012-0281-6] [Reference Citation Analysis]
325 D'Haens G, Feagan B, Colombel JF, Sandborn WJ, Reinisch W, Rutgeerts P, Carbonnel F, Mary JY, Danese S, Fedorak RN, Hanauer S, Lémann M; International Organization for Inflammatory Bowel Diseases (IOIBD) and the Clinical Trial Committee Clincom of the European Crohn's and Colitis Organisation (ECCO). Challenges to the design, execution, and analysis of randomized controlled trials for inflammatory bowel disease. Gastroenterology 2012;143:1461-9. [PMID: 23000597 DOI: 10.1053/j.gastro.2012.09.031] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 4.1] [Reference Citation Analysis]
326 Burri E, Manz M, Rothen C, Rossi L, Beglinger C, Lehmann FS. Monoclonal antibody testing for fecal calprotectin is superior to polyclonal testing of fecal calprotectin and lactoferrin to identify organic intestinal disease in patients with abdominal discomfort. Clin Chim Acta. 2013;416:41-47. [PMID: 23178549 DOI: 10.1016/j.cca.2012.11.008] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
327 Whitehead SJ, French J, Brookes MJ, Ford C, Gama R. Between-assay variability of faecal calprotectin enzyme-linked immunosorbent assay kits. Ann Clin Biochem. 2013;50:53-61. [PMID: 23129721 DOI: 10.1258/acb.2012.011272] [Cited by in Crossref: 72] [Cited by in F6Publishing: 77] [Article Influence: 7.2] [Reference Citation Analysis]
328 Liu JR, Sheng XY, Hu YQ, Yu XG, Westcott JE, Miller LV, Krebs NF, Hambidge KM. Fecal calprotectin levels are higher in rural than in urban Chinese infants and negatively associated with growth. BMC Pediatr. 2012;12:129. [PMID: 22917269 DOI: 10.1186/1471-2431-12-129] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 3.2] [Reference Citation Analysis]
329 Milestone A. The role of faecal calprotectin in IBD. Gastrointestinal Nursing 2012;10:22-23. [DOI: 10.12968/gasn.2012.10.4.22b] [Reference Citation Analysis]
330 Šenolt L. Calprotectin (a S100 protein) as a sensitive biomarker for rheumatoid arthritis: new perspectives for an old finding. International Journal of Clinical Rheumatology 2012;7:127-129. [DOI: 10.2217/ijr.12.1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
331 Kant P, Fazakerley R, Hull MA. Faecal calprotectin levels before and after weight loss in obese and overweight subjects. Int J Obes (Lond). 2013;37:317-319. [PMID: 22410961 DOI: 10.1038/ijo.2012.38] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
332 Kok L, Elias SG, Witteman BJ, Goedhard JG, Muris JW, Moons KG, de Wit NJ. Diagnostic accuracy of point-of-care fecal calprotectin and immunochemical occult blood tests for diagnosis of organic bowel disease in primary care: the Cost-Effectiveness of a Decision Rule for Abdominal Complaints in Primary Care (CEDAR) study. Clin Chem. 2012;58:989-998. [PMID: 22407858 DOI: 10.1373/clinchem.2011.177980] [Cited by in Crossref: 54] [Cited by in F6Publishing: 61] [Article Influence: 5.4] [Reference Citation Analysis]
333 Vilela EG, Torres HODG, Martins FP, Ferrari MLA, Andrade MM, Cunha ASD. Evaluation of inflammatory activity in Crohn’s disease and ulcerative colitis. World J Gastroenterol 2012; 18(9): 872-881 [PMID: 22408345 DOI: 10.3748/wjg.v18.i9.872] [Cited by in CrossRef: 61] [Cited by in F6Publishing: 69] [Article Influence: 6.1] [Reference Citation Analysis]
334 Riestra Menéndez S, de Francisco García R, Pérez-martínez I. Manejo extra-hospitalario de la enfermedad inflamatoria intestinal: papel de Atención Primaria. Medicine - Programa de Formación Médica Continuada Acreditado 2012;11:293-300. [DOI: 10.1016/s0304-5412(12)70301-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
335 Koulaouzidis A, Douglas S, Plevris JN. Blue mode does not offer any benefit over white light when calculating Lewis score in small-bowel capsule endoscopy. World J Gastrointest Endosc 2012; 4(2): 33-37 [PMID: 22347530 DOI: 10.4253/wjge.v4.i2.33] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
336 Bufler P, Groß M, Uhlig HH. In Reply. Deutsches Ärzteblatt international 2012. [DOI: 10.3238/arztebl.2012.0111] [Reference Citation Analysis]
337 Iskandar HN, Ciorba MA. Biomarkers in inflammatory bowel disease: current practices and recent advances. Transl Res. 2012;159:313-325. [PMID: 22424434 DOI: 10.1016/j.trsl.2012.01.001] [Cited by in Crossref: 125] [Cited by in F6Publishing: 135] [Article Influence: 12.5] [Reference Citation Analysis]
338 Manz M, Burri E, Rothen C, Tchanguizi N, Niederberger C, Rossi L, Beglinger C, Lehmann FS. Value of fecal calprotectin in the evaluation of patients with abdominal discomfort: an observational study. BMC Gastroenterol. 2012;12:5. [PMID: 22233279 DOI: 10.1186/1471-230x-12-5] [Cited by in Crossref: 50] [Cited by in F6Publishing: 56] [Article Influence: 5.0] [Reference Citation Analysis]
339 Ayling RM. New faecal tests in gastroenterology. Ann Clin Biochem. 2012;49:44-54. [PMID: 22113956 DOI: 10.1258/acb.2011.011150] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
340 Smith DJ, Reid DW, Bell SC. Treatment of pulmonary exacerbations in cystic fibrosis. Therapy 2011;8:623-643. [DOI: 10.2217/thy.11.77] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
341 Dolci A, Panteghini M. Comparative study of a new quantitative rapid test with an established ELISA method for faecal calprotectin. Clin Chim Acta 2012;413:350-1. [PMID: 21982915 DOI: 10.1016/j.cca.2011.09.030] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
342 Wassell J, Wallage M, Brewer E. Evaluation of the Quantum Blue® rapid test for faecal calprotectin. Ann Clin Biochem. 2012;49:55-58. [PMID: 21930735 DOI: 10.1258/acb.2011.011106] [Cited by in Crossref: 32] [Cited by in F6Publishing: 37] [Article Influence: 2.9] [Reference Citation Analysis]
343 Turvill J. High negative predictive value of a normal faecal calprotectin in patients with symptomatic intestinal disease. Frontline Gastroenterol 2012;3:21-8. [PMID: 28839626 DOI: 10.1136/flgastro-2011-100011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
344 Anderson N, Suliman I, Bandaletova T, Obichere A, Lywood R, Loktionov A. Protein biomarkers in exfoliated cells collected from the human rectal mucosa: implications for colorectal disease detection and monitoring. Int J Colorectal Dis. 2011;26:1287-1297. [PMID: 21698353 DOI: 10.1007/s00384-011-1263-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
345 Janczewska I, Nekzada Q, Kapraali M. Crohn's disease after gastric bypass surgery. BMJ Case Rep 2011;2011:bcr0720103168. [PMID: 22693320 DOI: 10.1136/bcr.07.2010.3168] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
346 Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology 2011;140:1817-1826.e2. [PMID: 21530748 DOI: 10.1053/j.gastro.2010.11.058] [Cited by in Crossref: 295] [Cited by in F6Publishing: 314] [Article Influence: 26.8] [Reference Citation Analysis]
347 Liu S, Richards SM, Lo K, Hatton M, Fay A, Sullivan DA. Changes in gene expression in human meibomian gland dysfunction. Invest Ophthalmol Vis Sci 2011;52:2727-40. [PMID: 21372006 DOI: 10.1167/iovs.10-6482] [Cited by in Crossref: 39] [Cited by in F6Publishing: 51] [Article Influence: 3.5] [Reference Citation Analysis]
348 Wassell J. Calprotectin testing in the community. Ann Clin Biochem 2011;48:1-2. [DOI: 10.1258/acb.2010.010245] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
349 Andréasson K, Scheja A, Saxne T, Ohlsson B, Hesselstrand R. Faecal calprotectin: a biomarker of gastrointestinal disease in systemic sclerosis. J Intern Med. 2011;270:50-57. [PMID: 21205026 DOI: 10.1111/j.1365-2796.2010.02340.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis]
350 Lamb CA, Mansfield JC. Measurement of faecal calprotectin and lactoferrin in inflammatory bowel disease. Frontline Gastroenterol. 2011;2:13-18. [PMID: 23904968 DOI: 10.1136/fg.2010.001362] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 2.6] [Reference Citation Analysis]
351 Péluchon R. Doser la calprotectine fécale éviterait bien des fibroscopies “inutiles”. Option/Bio 2010;21:6. [DOI: 10.1016/s0992-5945(10)70570-5] [Reference Citation Analysis]